WO2023060244A1 - Methods and compositions including novel antibodies for diagnosing covid-19 variants - Google Patents
Methods and compositions including novel antibodies for diagnosing covid-19 variants Download PDFInfo
- Publication number
- WO2023060244A1 WO2023060244A1 PCT/US2022/077774 US2022077774W WO2023060244A1 WO 2023060244 A1 WO2023060244 A1 WO 2023060244A1 US 2022077774 W US2022077774 W US 2022077774W WO 2023060244 A1 WO2023060244 A1 WO 2023060244A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- sars
- cov
- antibodies
- binding
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 208000025721 COVID-19 Diseases 0.000 title claims description 40
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 111
- 239000000427 antigen Substances 0.000 claims abstract description 84
- 108091007433 antigens Proteins 0.000 claims abstract description 82
- 102000036639 antigens Human genes 0.000 claims abstract description 82
- 230000035772 mutation Effects 0.000 claims abstract description 35
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims abstract description 32
- 101710198474 Spike protein Proteins 0.000 claims abstract description 10
- 229940096437 Protein S Drugs 0.000 claims abstract description 8
- 230000027455 binding Effects 0.000 claims description 109
- 239000012634 fragment Substances 0.000 claims description 55
- 238000012360 testing method Methods 0.000 claims description 43
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 41
- 241000282414 Homo sapiens Species 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 238000002965 ELISA Methods 0.000 claims description 26
- 238000003556 assay Methods 0.000 claims description 21
- 239000003937 drug carrier Substances 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000003612 virological effect Effects 0.000 claims description 13
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 claims description 12
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000003018 immunoassay Methods 0.000 claims description 7
- 239000004138 Stearyl citrate Substances 0.000 claims description 6
- 238000002405 diagnostic procedure Methods 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002122 magnetic nanoparticle Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 41
- 102000004169 proteins and genes Human genes 0.000 abstract description 35
- 241000700605 Viruses Species 0.000 abstract description 7
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 77
- 235000018102 proteins Nutrition 0.000 description 33
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 31
- 230000004048 modification Effects 0.000 description 31
- 238000012986 modification Methods 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000000523 sample Substances 0.000 description 24
- 238000001514 detection method Methods 0.000 description 23
- 238000011282 treatment Methods 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 238000011534 incubation Methods 0.000 description 18
- 239000002245 particle Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 239000012855 volatile organic compound Substances 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- -1 e.g. Proteins 0.000 description 13
- 230000003472 neutralizing effect Effects 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 12
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 12
- 238000006386 neutralization reaction Methods 0.000 description 12
- 239000000825 pharmaceutical preparation Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 241000494545 Cordyline virus 2 Species 0.000 description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 239000013638 trimer Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000012123 point-of-care testing Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000003118 sandwich ELISA Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000044437 S1 domains Human genes 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 241001529936 Murinae Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002773 nucleotide Chemical group 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 238000012124 rapid diagnostic test Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000013504 emergency use authorization Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 4
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940051243 etesevimab Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 229960004584 methylprednisolone Drugs 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 3
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 3
- 101710196709 Inosamine-phosphate amidinotransferase 1 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710141119 Putative inosamine-phosphate amidinotransferase 2 Proteins 0.000 description 3
- 108700036684 S1 domains Proteins 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000009167 androgen deprivation therapy Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940052143 bamlanivimab Drugs 0.000 description 3
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960000380 propiolactone Drugs 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 235000016804 zinc Nutrition 0.000 description 3
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 2
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
- 101710189104 Fibritin Proteins 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 229940126656 GS-4224 Drugs 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100025746 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102220590628 Spindlin-1_L18F_mutation Human genes 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 102000025171 antigen binding proteins Human genes 0.000 description 2
- 108091000831 antigen binding proteins Proteins 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 229940125388 beta agonist Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 238000013357 binding ELISA Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229940126587 biotherapeutics Drugs 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960003184 carprofen Drugs 0.000 description 2
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 229960000860 dapsone Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229960002224 eculizumab Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
- 229960004945 etoricoxib Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 229960001419 fenoprofen Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229960002714 fluticasone Drugs 0.000 description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 102000048657 human ACE2 Human genes 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940008228 intravenous immunoglobulins Drugs 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 229950007439 lenzilumab Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- 229960001929 meloxicam Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- HTNPEHXGEKVIHG-ZJTJHKMLSA-N molnupiravir Chemical compound CC(C)C(=O)OC[C@H]1O[C@H](C(O)C1O)N1C=C\C(NC1=O)=N\O HTNPEHXGEKVIHG-ZJTJHKMLSA-N 0.000 description 2
- 229940075124 molnupiravir Drugs 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960000965 nimesulide Drugs 0.000 description 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 2
- 229960004662 parecoxib Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960001315 sodium aurothiomalate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000005829 trimerization reaction Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
- 229960002004 valdecoxib Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 230000006295 S-nitrosylation Effects 0.000 description 1
- 230000006298 S-sulfinylation Effects 0.000 description 1
- 230000006302 S-sulfonylation Effects 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 1
- 102220590625 Spindlin-1_P26S_mutation Human genes 0.000 description 1
- 102220590630 Spindlin-1_T20N_mutation Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108091008108 affimer Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- OHDRQQURAXLVGJ-AXMZSLBLSA-N azane;(2z)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-AXMZSLBLSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000006242 butyrylation Effects 0.000 description 1
- 238000010514 butyrylation reaction Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940051183 casirivimab Drugs 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000035430 glutathionylation Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229940051184 imdevimab Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000017538 malonylation Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002113 nanodiamond Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001884 polyglutamylation Effects 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 230000019474 polyglycylation Effects 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 230000006267 polysialylation Effects 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000006289 propionylation Effects 0.000 description 1
- 238000010515 propionylation reaction Methods 0.000 description 1
- 101150025733 pub2 gene Proteins 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000012129 rapid antigen test Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102200056390 rs12204826 Human genes 0.000 description 1
- 102220277108 rs1553412687 Human genes 0.000 description 1
- 102200144284 rs235768 Human genes 0.000 description 1
- 102220033185 rs62646881 Human genes 0.000 description 1
- 102220058675 rs786203529 Human genes 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- VOCs Variants of Concern
- B.1.1.7 alpha, United Kingdom
- B.1.351 beta, South Africa
- P.1 gamma, Brazil
- B.1.617.2 delta, India
- VOCs can evade antibody immunity, whether provided by vaccination or passive immunization with monoclonal antibodies (mAbs).
- mAbs monoclonal antibodies
- VOCs are also more transmissible than earlier strains and therefore warrant enhanced mitigation practices.
- the VOCs pose a particular risk to health care facilities, congregate housing settings, public transportation hubs, and high-risk occupational environments.
- VOC point-of-care testing
- RBD spike protein receptor binding domain
- N501Y substitution One of the most common is the N501Y substitution, which occurs in the alpha, beta, and gamma VOCs.
- N501 residue lies on the “right shoulder” of the RBD, where it directly contacts the ACE2 receptor through hydrophobic interactions.
- N501Y has arisen simultaneously in many lineages and confers a selective advantage over Wuhan-Hu-1 (L) by increasing the affinity of the RBD for the ACE2 receptor 3- to 16-fold.
- An RBD mutation screen for high affinity ACE2 binding repeatedly produced de novo N501Y mutants, consistent with the worldwide appearance of multiple independent N501Y-containing variants.
- N501Y collaborates with other RBD mutations to increase binding and infectivity (e.g. E484K), and structural and functional studies suggest that N501Y will continue to circulate among SARS-CoV-2 variants via co- selection with mutations that resist antibody neutralization.
- Mu B.1.621 Variant of Interest
- Mu contains the RBD mutations R346K, E484K, and N501Y.
- N501Y has originated many times globally and is positively selected because it allows tyrosine side-chain interactions that increase infectivity through enhanced ACE2 binding. Mutagenesis and modeling experiments suggest that N501Y will be a feature of important variants likely to arise in the future, contributing to the spread of variants resistant to current anti-viral vaccines and therapeutics.
- NAATs Nucleic Acid Amplification Tests
- SGTF S-Gene Target Failure
- CRISPR CRISPR
- Absoassays that detect viral antigens e.g., Antigen-detection Rapid Diagnostic Tests (Ag- RDTs)
- Ag-RDTs are typically lateral flow assays (LFAs) that can be read within 15-30 minutes. They are less sensitive than NAATs, but they have high negative predictive values and are therefore ideal for POC testing, in which rapid turnaround time and high testing frequency are essential for pandemic control.
- SARS-CoV-2 Ag-RDTs have been granted an Emergency Use Authorization by the FDA.
- variant-specific tests have not yet been implemented
- SUMMARY OF THE INVENTION Antibodies, compositions, and methods for diagnosing and treating COVID-19 variants are provided herein.
- an antibody that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Wuhan S1 protein variant at N501, but does not bind a SARS-CoV-2 S1 protein variant that has a spike protein mutation N501Y is provided.
- the antibody includes: (a) a heavy chain variable region (V H ) comprising (i) a complementarity- determining region 1 (CDR1) of SEQ ID NO: 15, (ii) a complementarity-determining region 2 (CDR2) of SEQ ID NO: 17, and (iii) a complementarity-determining region 3 (CDR3) of SEQ ID NO: 18; and/or (b) a light chain variable region (V L ) comprising, (i) a CDR1 of SEQ ID NO: 22, (ii) a CDR2 having the amino acid sequence Asp-Asp-Ser (DDS), and (iii) a CDR3 of SEQ ID NO: 23.
- V H heavy chain variable region comprising (i) a complementarity- determining region 1 (CDR1) of SEQ ID NO: 15, (ii) a complementarity-determining region 2 (CDR2) of SEQ ID NO: 17, and (iii) a complementarity-determining region 3 (CDR3) of
- the antibody includes a V H having an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 14 and/or a V L having an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 21. In one embodiment, the antibody includes a V H comprising the amino acid sequence of SEQ ID NO: 14 and a V L comprising the amino acid sequence of SEQ ID NO: 21.
- the antibody is formatted as a non-human antibody, wherein the V H has CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 15, 17, and 18, respectively, and wherein the V L has CDR1, CDR2, and CDR3 sequences of SEQ ID NO: 22, amino acid sequence DDS and SEQ ID NO: 23, respectively.
- a method of diagnosing a subject as being infected with a SARS- CoV-2 virus or screening a subject for a SARS-CoV-2 infection is provided.
- the method includes contacting a sample obtained from the subject with at least one antibody or a panel of antibodies that bind selected S1 antigens in SARS-CoV-2 variants to form an antibody/SARS-CoV-2 virus complex when the antigen is present in the sample.
- One antibody in the panel of antibodies is an antibody as described herein that binds S1 antigens having only residue N501, not mutations at that site.
- the method further includes detecting the pattern of binding between said antibodies by the presence or absence of an antibody/SARS-CoV-2 virus complex, and diagnosing the subject as being infected with a specific SARS-CoV-2 virus variant based upon the pattern of binding between the panel of antibodies and the viral S1 protein.
- the test is an Antigen Diagnostic Test immunoassay directed to detect at pattern of spike RBD polymorphisms at S1 amino acid residues K417, L452, E484, and N501, wherein the pattern detected by the selected antibodies or antigen binding fragments thereof distinguishes among SARS-CoV-2 variant infections.
- a method of diagnosing a subject as being infected with a SARS- CoV-2 virus or screening a subject for a SARS-CoV-2 infection includes contacting a sample obtained from the subject with at least one antibody or a panel of antibodies that bind selected S1 antigens in SARS-CoV-2 variants to form an antibody/SARS-CoV-2 virus complex when the antigen is present in the sample.
- the method includes contacting a sample obtained from the subject with an antibody that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Wuhan S1 protein variant at N501, but does not bind a SARS-CoV-2 S1 protein variant that has a spike protein mutation N501Y, to form an antibody/SARS-CoV-2 virus complex when the antigen is present in the sample.
- the subject is diagnosed as being infected with a SARS-CoV-2 virus variant having the residue N501 and not N501Y, when the antibody/SARS-CoV-2 virus complex is detected.
- the test further comprises a pan-SARS-CoV-2 specific antibody.
- a diagnostic composition is provided.
- the composition includes an antibody as described herein, conjugated to or associated with a detectable label.
- a transformed cell that expresses an antibody as described herein.
- a diagnostic kit for the diagnosis of a SARS-CoV-2 variant is provided.
- the diagnostic kit includes an antibody as described herein, conjugated to or associated with a detectable label.
- the kit includes a pan-SARS- CoV-2 specific antibody, conjugated to or associated with a detectable label.
- a pharmaceutical composition is provided.
- the composition includes an antibody as described herein, and a pharmaceutically acceptable carrier.
- the composition includes a second therapeutic agent.
- a method of preventing or treating a SARS-CoV-2 viral infection or COVID19 in a subject in need thereof includes administering to the subject a therapeutically effective amount of the composition that includes an antibody as described herein.
- FIG.1A – FIG.1D show SARS-CoV-2 L strain (Wuhan-Hu-1) spike binding by the 2E8 human mAb.
- FIG.1B S1 binding to 293T-hsACE2 cells in the presence of 2E8, 4G1 (isotype control IgG), CR3022, CB6, and an ACE2-Fc fusion protein was assessed by flow cytometry.
- FIG.2A – FIG.2D show epitope binning for 2E8 on the SARS-CoV-2 S1 and RBD.
- L-type spike FIG.2A, FIG.2C
- RBD FIG.2B, FIG.
- FIG.3A – FIG.3C show differential recognition of SARS-CoV-2 variant spike antigen by direct ELISA.
- FIG.3A – FIG.4B show differential recognition of SARS-CoV-2 variant spike antigens using a sandwich ELISA with human mAbs.
- FIG.5 shows a full immobilization sequence of the SARS-CoV-2 S1 domain. The antigen was adhered via a His-tag onto an NTA Sensor in Active (Channel 2).
- FIG.6 shows anti-spike antibody 2E8 binding to the immobilized S1 domain.
- the initial non-specific binding (NSB) test on the NTA sensor is performed with PBST supplemented with 0.1% BSA to reduce non-specific binding. Decreasing concentrations are displayed, starting with the highest concentration at the top.
- FIG.7A – FIG.7C show pseudotyped VSV-G:S1 and S1 trimer antigens. (FIG.7A) SDS:PAGE demonstrating proteins contained in the VSV-G:S1 pseudotyped particles.
- FIG.7B SDS:PAGE of the S1 trimer, analyzed as reduced and non-reduced (NR) samples.
- FIG.7C Map of the gene encoding the S1 trimer.
- FIG.8A and FIG.8B provide the heavy chain (FIG.8A; SEQ ID NO: 1) and light chain (FIG.8B; SEQ ID NO: 8) variable region sequences for the 2E8 mAb, including CDRs and framework regions.
- FIG.9A and FIG.9B provide an overview of a solid support diagnostic device having sequentially arranged reaction zones.
- the present invention comprises antibodies, compositions, and methods useful for detection of specific SARS-CoV-2 variants by detecting variant specific antigens.
- the described antibodies are useful as a component of antigen-detection rapid diagnostic tests (Ag-RDTs) that can be used in point-of-care and repeat testing situations to diagnose active COVID-19 cases in 15-30 minutes.
- Ag-RDTs antigen-detection rapid diagnostic tests
- Described herein, in one embodiment is a monoclonal antibody, designated as 2E8, that specifically binds to SARS-CoV-2 spike protein that contain an aspargine at position 501 (N501) and does not bind to SARS-CoV-2 spike proteins that contain a common mutation that occurs in many variants of concern (N501Y).
- the mAb 2E8 is useful in compositions, methods, and kits to immediately detect cases of variants that contain the N501Y mutation within the current background of delta (B.1.617.2) global predominance. Twenty-five Ag- RDTs have been granted an EUA by the FDA. None of these are antigen specific. The mAbs described in the present invention could be adapted by these companies to produce variant- specific Ag-RDTs.
- Technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs and by reference to published texts, which provide one skilled in the art with a general guide to many of the terms used in the present application. The definitions contained in this specification are provided for clarity in describing the components and compositions herein and are not intended to limit the claimed invention.
- a or “an” refers to one or more.
- an expression cassette is understood to represent one or more such cassettes.
- the terms “a” (or “an”), “one or more,” and “at least one” are used interchangeably herein.
- the term “about” means a variability of plus or minus 10 % from the reference given, unless otherwise specified.
- the words “comprise”, “comprises”, and “comprising” are to be interpreted inclusively rather than exclusively, i.e., to include other unspecified components or process steps.
- the words “consist”, “consisting”, and its variants, are to be interpreted exclusively, rather than inclusively, i.e., to exclude components or steps not specifically recited.
- antibody or “antibody molecule” is any immunoglobulin, including antibodies and fragments thereof, that binds to a specific antigen.
- antibody or antibody molecule contemplates intact immunoglobulin molecules, immunologically active portions of an immunoglobulin molecule, and fusions of immunologically active portions of an immunoglobulin molecule.
- the antibodies described herein are capable of specifically complexing with, binding to, identifying or detecting an epitope of an antigen, e.g., SARS-CoV-2 spike variants with N501 but not N501Y.
- an “antibody” includes, in addition to antibodies comprising two full-length heavy chains (each chain comprising a variable region and a constant region) and two full-length light chains (each chain comprising a variable region and a constant region), modifications, antigen or epitope binding fragments, as well as “antibody mimics” or “antibody equivalents” or muteins thereof.
- an “antibody” refers to an intact immunoglobulin, such as an IgA, IgD, IgE, IgG, and IgM, or to an antigen binding portion thereof that competes with the intact antibody for specific binding, unless otherwise specified.
- an intact antibody is an IgG1, IgG2, IgG3 or IgG4.
- Heavy and light chain variable domain sequences and CDRs may be selected from those described herein, including in those provided in FIG.8A and FIG.8B and the in the Sequence Listing, e.g., SEQ ID NOs: 1-26.
- an “antibody” or “antigen/epitope binding fragment” as described herein refers to an anti-SARS-CoV-2 spike protein antibody designated 2E8 or fragment thereof based upon the sequences defined herein.
- Such an antibody or fragment includes a monoclonal antibody, a synthetic antibody, a recombinant antibody, a chimeric antibody, a humanized antibody, a human antibody, a CDR-grafted antibody, a multi-specific binding construct that can bind two or more epitopes, a dual specific antibody, a bi-specific antibody, a multi-specific antibody, an affinity matured antibody, a single antibody chain or an scFv fragment, a diabody, a single chain comprising complementary scFvs (tandem scFvs) or bispecific tandem scFvs, an Fv construct, a disulfide-linked Fv, a Fab construct, a Fab' construct, a F(ab')2 construct, an Fc construct, a monovalent or bivalent construct from which domains non-essential to monoclonal antibody function have been removed, a single-chain molecule containing one V L (variable region of light chain), one V H (variable region
- Recombinant antibody refers to an antibody that is expressed from a cell or cell line transfected with one or more expression vectors comprising a coding sequence of the antibody, where said coding sequence is not naturally associated with the cell or naturally occurred in the cell.
- Said cell may be termed as a host cell.
- the host cell may be a non-human cell or non-human cell line.
- the host cell may be a non-mammalian cell or cell line, for example, an insect cell or cell line, a yeast cell or cell line, or an E coli cell or cell line.
- the host cell may be a mammalian cell or cell line. In certain embodiments, the host cell may be a non-human mammalian cell or cell line. In certain embodiments, the host cell may be a human cell or cell line, for example a human embryonic kidney 293 cells or a hybridoma cell or cell line.
- a recombinant antibody has a glycosylation pattern that is different than the glycosylation pattern of an antibody having the same sequence if it were to exist in nature. In one embodiment, a recombinant antibody is expressed in a mammalian host cell which is not a human host cell. Notably, individual mammalian host cells have unique glycosylation patterns.
- the antibody is produced using the on-cell mAb screening system described by Puligedda et al, MAbs, 2019 Apr;11(3):546-558. doi: 10.1080/19420862.2019.1574520. Epub 2019 Feb 22, which is incorporated herein by reference. Methods for producing such antibodies are well-known in the art. Indeed, commercial vectors for certain antibody and antibody fragment constructs are available.
- the antibody may also be a protein (e.g., a fusion protein) comprising at least one antibody or antibody fragment.
- the antibody comprises an Fc region.
- these anti- antibodies and fragments thereof have a binding affinity (Ka) for an epitope of at least 10 3 M.
- the antigen binding proteins exhibit a Ka of at least 10 3 M, at least 10 4 M, at least 10 5 M, or at least 10 6 M.
- an “antibody mimic” or an “antibody equivalent” refers to a molecule (for example, an amino acid sequence, a protein, or a modified or conjugated version thereof).
- affibodies i.e., a class of engineered affinity proteins, generally small ( ⁇ 6.5 kDa) single domain proteins that can be isolated for high affinity and specificity to any given target, aptamers, polypeptide molecules that bind to a specific target, an affilin, an affitin, an affimer, an alphabody, an anticalin, an avimer, a DARPin (designed ankyrin repeat proteins), a Fynomer, a Kunitz domain peptide, a monobody, a peptabody and others known in the art.
- a “modification” of an amino acid sequence comprises an amino acid sequence wherein one or more amino acid residues are inserted into, deleted from, or substituted into the reference amino acid sequence, e.g., any of amino acid sequence encoding the variable light or heavy chains, and/or CDRs of antibody 2E8.
- One such modification is the replacement of one amino acid in such a sequence, e.g., any of SEQ ID NO: 1 to 26, with a conservative amino acid.
- Other modifications include, for example, fusion proteins formed by fusing the heavy chain of a selected antibody into an Ig backbone.
- Still another modification includes an antibody that has been modified via conjugation to another chemical moiety (such as, for example, polyethylene glycol or albumin, e.g., human serum albumin), or a post-translational modification, such as phosphorylation, glycosylation, acylation, acetylation, formylation, alkylation, amidation, arginylation, polyglutamylation, polyglycylation, butyrylation, gamma- carboxylation, polysialylation, malonylation, hydroxylation, iodination, nucleotide addition, phosphate ester or phosphoramidate, propionylation, pyroglutamate formation, S- glutathionylation, S-nitrosylation, S-sulfinylation, S-sulfonylation, succinylation addition of a succinyl group to lysine, and sulfation.
- another chemical moiety such as, for example, polyethylene glycol or albumin,
- a modification of antibody 2E8 is a single chain human antibody, having a variable domain region from a heavy chain and a variable domain region from a light chain and a peptide linker connecting the heavy chain and light chain variable domain regions.
- an antibody construct e.g., an antibody, an antibody heavy chain, an antibody light chain, or any fragment or modification thereof
- CDRs Complementarity-Determining Regions
- FRs framework regions
- CDRs are arranged non- consecutively, not immediately adjacent to each other, and may be separated by an FR.
- CDRs are where an antigen specifically binds.
- the antibody has one or more of the CDRs set forth in the table below.
- the antibody has 1, 2, or all three of the CDRs from the heavy chain. In some embodiments, the antibody has 1, 2, or all three of the CDRs from the light chain. In some embodiments, the antibody has all 6 CDRs as described below. Table 1: 2E8 Antibody Variable Chain CDRs It would be understood by one of skill in the art that the antibody constructs, fragments or modifications, and CDR described herein may be used in any embodiment, composition, reagent, or method, including those also described herein. It would also be understood that an antibody, antibody construct, fragment or modification provided herein may comprise an FR or a non-CDR J-region, other than those identified provided in the incorporated Sequence Listing.
- Such an antibody, antibody construct, fragment or modification may have a binding affinity and/or specificity to its SARS-CoV2 spike protein epitope or antigen at about 20%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 97%, about 99%, about 100%, more than about 100%, about 200%, about 300%, or about 500% of that of any antibody constructs described in this specification.
- Conventional methods including enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), MSD assay, and antibody phage display library, may be used to determine such binding affinity and/or specificity.
- the term “immunologically specific” refers to proteins or polypeptides, particularly antibodies, that bind to one or more epitopes of a protein or compound of interest, but which do not substantially recognize and bind other molecules in a sample containing a mixed population of antigenic biological molecules.
- An “epitope” as used herein refers to the portion of a SARS-CoV2 spike protein or any naturally occurring or synthetic or recombinant amino acid sequence that is capable of specifically complexing with one or more of the antibodies or fragments or modified antibodies, as described herein.
- An epitope can comprise non-contiguous portions of the molecule (e.g., in a polypeptide, amino acid residues that are not contiguous in the polypeptide's primary sequence but that, in the context of the polypeptide's tertiary and quaternary structure, are near enough to each other to be bound by an antigen binding protein).
- the epitope to which an anti-SARS-CoV2 spike protein antibody as described herein binds includes the residue N501 but not N501Y. See, Liu, H., Zhang, Q., Wei, P. et al. The basis of a more contagious 501Y.V1 variant of SARS-CoV-2.
- Percent (%) identity in the context of amino acid sequences or nucleotide sequences refers to the residues in the two sequences which are the same when aligned for correspondence. Percent identity may be readily determined for amino acid sequences or nucleotide sequences over the full-length of a protein, polypeptide, or encoding region thereof, e.g., about 15 amino acids, about 150 amino acids, or a peptide fragment thereof or the corresponding nucleic acid sequence coding sequences.
- a suitable amino acid fragment may be at least about 4 amino acids in length and may be up to about 200 or up to about 700 amino acids or nucleotide fragments of from about 12 nucleotides to about 600 to 2100 nucleotides.
- identity when referring to “identity”, “homology”, or “similarity” between two different sequences, “identity”, “homology” or “similarity” is determined in reference to “aligned” sequences.
- alignd sequences or “alignments” refer to multiple nucleic acid sequences or protein (amino acids) sequences, often containing corrections for missing or additional bases or amino acids as compared to a reference sequence. Alignments are performed using any of a variety of publicly or commercially available Multiple Sequence Alignment Programs.
- Sequence alignment programs are available for amino acid sequences, e.g., the “Clustal Omega”, “Clustal X”, “MAP”, “PIMA”, “MSA”, “BLOCKMAKER”, “MEME”, and “Match-Box” programs. Generally, any of these programs are used at default settings, although one of skill in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program which provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. See, e.g., (THOMPSON et al.1999).
- the “conservative amino acid replacement” or “conservative amino acid substitutions” refers to a change, replacement or substitution of an amino acid to a different amino acid with similar biochemical properties (e.g., charge, hydrophobicity and size), which is known by practitioners of the art. Also see, e.g., FRENCH et al.1983, and YAMPOLSKY et al.2005. In certain embodiments, a CDR of the disclosed antibody or fragment thereof is free of conservative amino acid replacement.
- “Patient” or “subject” or “host” as used herein means a male or female mammalian animal, including a human, a veterinary or farm animal, a domestic animal or pet, and animals normally used for clinical research.
- the subject of these methods and compositions is a human.
- prevent refers to the prophylactic treatment of a subject who is at risk of developing a condition resulting in a decrease in the probability that the subject will develop the condition.
- treat refers to any type of treatment that imparts a benefit to a patient afflicted with a disease, including improvement in the condition of the patient (e.g., in one or more symptoms), delay in the progression of the condition, or reduction in severity of the disease and its symptoms.
- “disease”, “disorder” and “condition” are used interchangeably, to indicate an abnormal state in a subject.
- a “therapeutically effective amount” of a compound or a pharmaceutical composition refers to an amount effective to prevent, inhibit, treat, or lessen the symptoms of a particular disorder or disease.
- “Pharmaceutically acceptable” indicates approval by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- a “carrier” refers to, for example, a diluent, adjuvant, excipient, auxiliary agent or vehicle with which an active agent of the present invention is administered.
- Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described, for example, in “Remington's Pharmaceutical Sciences” by E.W. Martin. Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- Water or aqueous saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions.
- the pharmaceutically acceptable carrier of the composition is selected from the group of diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers.
- compositions can include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; and additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80), antioxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol).
- the compositions can also be incorporated into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc., or into liposomes or nanoparticles.
- a “reaction zone” is defined as a region on the solid support of a diagnostic device containing predetermined concentrations of capture antibodies, attached to the solid support, each capture antibody capable of recognizing and binding a distinct epitope of a test protein or antigen (i.e., SARS-CoV-2 spike protein).
- the reaction zone can be any designated region or portion of a membrane strip, or it can be in a container such as a test tube, or it can consist of a well in a microtiter plate.
- the reaction zone provides a specific location for detecting the presence and range of concentration of an antigen in a biological sample.
- a “reagent zone” is defined as a region of a diagnostic device as described herein containing a mixture of incubation antibodies that are identical in type to the capture antibodies in the reaction zone, and a detection antibody.
- the reagent zone is preferably provided on the device as a designated region or portion of a membrane strip.
- the reagent zone is separate from the solid support containing the reaction zones for example, in a container such as a test tube or as a well in a microtiter plate.
- a test protein or antigen i.e., SARS-CoV-2 spike protein in a sample is exposed to the reagent zone prior to being exposed to any reaction zone.
- the reagent zone is typically formed using an incubation solution containing incubation antibodies and other reagents, such as inert proteins and non-ionic detergent, to solubilize the test antigen and antibodies, and to reduce non-specific binding of the test antigen and antibodies.
- a “capture antibody” is defined as an antibody, attached to the solid support of the device of the invention in a reaction zone.
- Each capture antibody is selected to recognize and bind a particular, distinct epitope of the test protein or antigen (i.e., SARS- CoV-2 spike protein at a predetermined concentration, and is identical in type to an incubation antibody in the reagent zone.
- a “detection antibody” is defined as an antibody, that recognizes and binds the test protein or antigen (i.e., SARS-CoV-2 spike protein) at a binding site or epitope distinct from that of the incubation and capture antibodies.
- the detection antibody is coupled to a detectable label such as a chromophore, enzyme, radioisotope, or colored particle, such as colloidal gold or color latex.
- enzymes include, but are not limited to, alkaline phosphatase, beta galactosidase, or horseradish peroxidase which produce color when incubated with the appropriate substrate.
- concentration of detection antibody to use in the device of the invention is predetermined by conducting experiments to determine amounts of detection antibodies that are needed to provide a detectable signal. It should be understood that while various embodiments in the specification are presented using “comprising” language, under various circumstances, a related embodiment is also described using “consisting of” or “consisting essentially of” language. “Comprising” is a term meaning inclusive of other components or method steps.
- Antibody 2E8 Provided herein is a monoclonal antibody, designated 2E8, that distinguishes between SARS-CoV-2 spike variants with N501 and N501Y.
- the term “2E8 antibody” may refer to the monoclonal antibody described herein derived from the hybridoma or antibodies that contain fragments derived from that sequence.
- an ScFv having the variable heavy chain of the 2E8 monoclonal antibody and the variable light chain of the 2E8 monoclonal antibody may be referred to herein as the 2E8 antibody.
- Recombinant, synthetic, monoclonal or other antibodies or fragments that bind to one or more SARS-CoV2 spike protein epitopes that include the residue N501 include, in one embodiment a heavy chain variable domain SEQ ID NO: 14 and/or light chain variable domain sequence SEQ ID NO: 21 (antibody 2E8), or sequences at least 80% (for example, about 85%, about 86%, about 87% about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100%) identical thereto.
- antibodies or fragments that bind to one or more SARS-CoV2 spike protein epitopes that include the residue N501 include any one or two or all three CDRs of the heavy chain of antibody 2E8. In certain embodiments, antibodies or fragments that bind to one or more epitopes that include the residue N501 include any one or two or all three CDRs of the light chain of antibody 2E8. In certain embodiments, antibodies or fragments that bind to one or more epitopes that include the residue N501 include any one or two or three or four or five or all six CDRs of antibody 2E8.
- the nucleic acid sequence is suitable for expression of the antibodies or fragments thereof in a host cell. Fragments of antibody 2E8 heavy chain nucleotide sequence SEQ ID NO: 1 and amino acid sequence SEQ ID NO: 14 include those sequences identified in the table below. Table 2: Heavy Chain Variable Sequence of mAb 2E8
- Fragments of antibody 2E8 light chain nucleotide sequence SEQ ID NO: 8 and amino acid sequence SEQ ID NO: 21 include those sequences identified in the table below.
- Table 3 Light Chain Variable Sequence of mAb 2E8
- the antibodies and antibody constructs may be further modified from those exemplified.
- the domains of the antibody or antibody fragment have at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% homology or identity with the domains present in the anti- monoclonal antibody 2E8, and illustrated in the sequences identified in herein, in the Sequence Listing, and the tables above.
- the domains in the tables may be longer or shorter than the domains identified in the tables by about 1, 2, 3, 4, or 5, amino acids, particularly 1 or 2 amino acids, at the N terminus and/or C-terminus of the domain.
- the domains may be encoded by nucleotide sequences longer or shorter than those in the Sequence listings by 3, 6, 9, 12, or 15 nucleotides, particularly 3 or 6 nucleotides, at the 5’ terminus and/or 3’ terminus of the sequence encoding a domain.
- the CDR of an antibody can be determined by one of skill in the art, for example, via various databases, software, or algorithms. See, www.imgt.org.
- the CDRs are illustrated in FIG.8A and FIG.8B as well as provided in Table 2 and Table 3.
- the CDRs comprises one or two or three or four or five or six more or less amino acids at the N-terminal side and/or C-terminal side of the CDRs as illustrated herein.
- the CDRs are shifted toward the N- terminal side or the C-terminal side by one or two or three or four or five or six or seven or eight or nine or ten amino acid(s) compared to the ones as illustrated in FIG.8A and FIG.8B and provided in Table 2 and Table 3.
- the antibodies may be converted into a non- human immunoglobulin format.
- the selected sequences of the heavy or light chains of any of the antibodies disclosed herein are inserted into the backbone of a non-human antibody or antibody fragment construct.
- the variable light domain and/or variable heavy domain of the antibodies described herein may be inserted into another antibody construct.
- Still another embodiment comprises a fully human Fab antibody fragment having a heavy chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 14; or having a light chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 21 or combinations thereof.
- antibodies having a heavy chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 14, and a light chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 21, and combinations thereof, with a peptide linker connecting the heavy and light chains.
- a heavy chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 14
- a light chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 21, and combinations thereof, with a peptide linker connecting the heavy and light chains.
- polyclonal antibody compositions are typically produced by immunizing a selected mammal, e.g., a primate, rodent, or human, with a peptide/ polypeptide composition containing a specific epitope.
- polyclonal antibody molecules can be isolated from the mammal, e.g., from the whole blood, plasma or serum, and further purified from the plasma or serum of the immunized mammal by conventional techniques. Conventional harvesting techniques can include plasmapheresis, protein A and G chromatography, among others. Such polyclonal antibody compositions may themselves be employed as pharmaceutical compositions as described herein.
- monoclonal antibodies are made by now conventional techniques, using antibody producing cells obtained from the immunized mammals and fused to non-IgG-producing myeloma cells to form hybridomas or from selection from activated immune B cells with extraction by known molecular biological techniques.
- These monoclonal antibodies can be further used to prepare other forms of antibodies, e.g., chimeric antibodies, humanized antibodies, human antibodies.
- Other antibody fragments or ligands can be produced by screening phage display libraries, antibody fragments and mixtures thereof. Techniques for generating these types of antibodies and ligands are well-known in the art and the ligands themselves may be generated using the disclosed amino acid sequences of the above-identified epitopes.
- Chimeric antibodies may similarly be developed using known techniques. Chimeric antibodies are molecules in which different portions are derived from different animal species. Single chain antibodies may also be prepared by conventional methods, such as described in US Patent Nos.4,946,778 and 4,704,692 using the variable portions of the polyclonal or monoclonal antibodies produced according to this invention. The production of bi-specific antibodies or ligands that specifically bind to two or more selected epitopes, can employ conventional techniques. See, e.g., Hornig N, Desirber- Schwarz A., “Production of bispecific antibodies: diabodies and tandem scFv.”, 2012, Methods Mol Biol., 907:713-27; Speiss, C.
- In vitro transcription and translation systems are commercially available, e.g., from Promega Biotech (Madison, WI) or Gibco-BRL (Gaithersburg, MD).
- the antibodies, epitope-binding fragments or modifications thereof may also be produced by expression in a suitable prokaryotic or eukaryotic system.
- modifications may be inserted by use of a variety of CRISPR techniques and other related, e.g., zinc finger, methodologies for modifying amino acid and nucleotide sequences.
- Antibody recombinant engineering techniques are well-taught in the art including in publications, texts and reviews, such as Edwards, W. B., Xu, B., Akers, W., Cheney, P.
- the antibodies of the instant invention may also be conjugated/linked to other components.
- the antibodies may be operably linked (e.g., covalently linked, optionally, through a linker) to at least one detectable agent, imaging agent, contrast agent, or therapeutic compound (e.g., see above).
- the antibodies of the instant invention may also comprise at least one purification tag (e.g., a His-tag).
- the antibody molecules of the invention may be prepared using a variety of methods known in the art. Polyclonal and monoclonal antibodies may be prepared as described in Current Protocols in Molecular Biology, Ausubel et al. eds. Antibodies may be prepared by chemical cross-linking, hybrid hybridoma techniques and by expression of recombinant antibody fragments expressed in host cells, such as bacteria or yeast cells. In one embodiment of the invention, the antibody molecules are produced by expression of recombinant antibody or antibody fragments in host cells. The nucleic acid molecules encoding the antibody may be inserted into expression vectors and introduced into host cells. The resulting antibody molecules are then isolated and purified from the expression system. The antibodies optionally comprise a purification tag by which the antibody can be purified.
- the purity of the antibody molecules of the invention may be assessed using standard methods known to those of skill in the art, including, but not limited to, ELISA, immunohistochemistry, ion-exchange chromatography, affinity chromatography, immobilized metal affinity chromatography (IMAC), size exclusion chromatography, polyacrylamide gel electrophoresis (PAGE), western blotting, surface plasmon resonance and mass spectroscopy. Still other antibody modifications employing the SEQ ID Nos disclosed herein, e.g., as taught by the techniques referenced in above-cited US Patent Publication No. US2019/0062452, incorporated by reference herein. Diagnostic Methods In another aspect, the anti-SARS-CoV-2 antibodies described herein are useful in diagnosing COVID-19 infection.
- 2E8 a human antibody that binds the Wuhan-Hu-1 spike having N501 with high affinity, but does not bind variants containing the N501Y mutation.
- This mutation is shared among the Variants Being Monitored (VBMs) alpha, B.1.1.7, beta, B.1.351, gamma, P.1., and mu B.1.621.
- VBMs Variants Being Monitored
- B.1.167 identifying of a SARS-CoV-2 strain that does not bind 2E8 will reveal an infection with a non-delta strain.
- ADT antigen diagnostic test
- N501 The residue recognized by the 2E8 antibody, N501, lies on the “right shoulder” of the RBD and is involved in hydrophobic interactions with ACE2 during receptor binding [Vazquez-Lombardi R., et al. Nat. Protoc.2018;13:99–117; Tursi S.A., et al., et al. Nat. Commun.2020;11:1007].
- the N501Y mutation does not appear to globally alter the structure of the spike, rather, it allows tyrosine side-chain interactions that enhance ACE2 binding affinity that likely mediate the increased infectivity of N501Y-containing viruses [Vazquez- Lombardi R., et al. Nat.
- a method of detecting, or screening for, a SARS-CoV-2 infection in a subject includes contacting a sample from the subject with a 2E8 antibody, as described herein, wherein, in the presence of a SARS-CoV-2 spike protein having the N501 residue, binds the same, and detecting the bound complex.
- sample includes any product produced by a subject, or a product derived therefrom.
- a sample may be taken from any tissue or bodily fluid, e.g., a blood sample (including blood- derived samples), serum sample, lymph sample, saliva sample, synovial fluid sample, phlegm, nasal swab, etc.
- a blood-derived sample may be a selected fraction of a patient's blood, e.g., a selected cell-containing fraction, or a plasma or serum fraction.
- the sample is a nasal swab.
- the antibodies are useful in an assay, such as an immunoassay, for detecting or typing a SARS-CoV-2 infection in a subject.
- the immunoassay is an ELISA, or “sandwich assay”.
- one antibody is coupled to a solid support, and a second antibody is coupled to a detectable label.
- a test antigen having separate binding sites (epitopes) for the first and second antibodies is exposed to the antibody coupled to the solid support such that the antigen binds to that antibody.
- the labeled second antibody is added to the support to permit the binding of the labeled second antibody to the test antigen.
- detectable labels include chromophores, radioisotopes, or enzymes which can be converted into a product that can be measured photometrically.
- the 2E8 antibodies may be used alone, or in conjunction with other antibodies, in sandwich and other types of assays, to provide a specific diagnosis of the SARS-CoV-2 variant in a clinical sample.
- the 2E8 antibody binds the SARS-CoV-2 delta strain, but not alpha, beta, or gamma.
- the 2E8 antibody may be used in conjunction with a second antibody that can be used as a positive control for the presence of SARS-CoV-2, in which the second antibody binds SARS-CoV-2 spike protein regardless of the amino acid at position 501.
- An example here is the anti 6XHIS tag antibody, which binds a polypeptide tag appended to the N terminus of the recombinant spike proteins tested.
- any of a number of pan-SARS-CoV-2 specific antibodies could be used that are known to be state of the art.
- an additional mAb could be used.
- An example shown in the instant invention is CB6, which binds alpha and gamma strains, but not beta, and therefore differentiates among the N501Y mutated strains by providing specific binding to B.1.1.7 and P.1, but no binding to B.1.351.
- the antibody is useful in an ADT.
- the ADT includes a diagnostic device that includes a solid support, such as a membrane strip, having a plurality of sequentially arranged reaction zones, and preferably, at least one reagent zone (FIG.9A, FIG.9B, well A).
- the membrane strip may be made of synthetic or natural materials, such as polystyrene, nylon, nitrocellulose membrane, or filter paper.
- the reaction zones contain capture antibodies that bind epitopes of a SARS-CoV-2 spike protein.
- the strip contains one reaction zone, that contains the 2E8 antibody as the capture antibody.
- the strip contains at least one additional reaction zone, wherein one of the additional reaction zones includes a capture antibody that binds alpha and gamma strains, but not beta or delta.
- the strip contains at least one additional reaction zone, wherein one of the additional reaction zones includes a capture antibody that presumptively binds all strains of SARS-CoV-2.
- the solid support permits a solution containing the sample being assayed to be transferred to each of the reaction zones by diffusion, or by physical means, such as pipetting (FIG.9A and FIG.9B).
- suitable solid supports include, but are not limited to, microtiter plates, chromatographic membranes, or other immunoassay devices such as silica chips (Affmatrix, Palo Alto, Calif.).
- the 2E8 capture antibody is attached at the first reaction zone (well B)
- the C6B capture antibody is attached at the second reaction zone (well C)
- a capture antibody that presumptively binds all COVID-19 strains is attached at the third reaction zone.
- the capture antibodies are attached to the membrane strip, for example, by physical attachment as a result of the “stickiness” of the antibodies, or by chemical reaction coupling, so that they will not become soluble and detach when the membrane strip becomes wet.
- the capture antibodies can be understood to generally form a solid phase in the reaction zones.
- the solid support is provided without a reagent zone, and the sample is administered directly into the first reaction zone, and optionally additional reaction zones.
- the ADT includes a detection antibody.
- the detection antibody may be an antibody that binds to a different antigen on the SARS-CoV-2 spike protein.
- the 2E8 antibody is biotinylated, and the antibody-antigen binding is detected with, e.g., a streptavidin-HRP conjugate.
- the reactions are then developed with OPD substrate.
- Other enzyme substrates are known in the art and useful herein and include, without limitation, TMB (3,3',5,5'-tetramethylbenzidine), ABTS (2,2'-Azinobis [3- ethylbenzothiazoline-6-sulfonic acid]-diammonium salt, OPD (o-phenylenediamine dihydrochloride), PNPP (p-Nitrophenyl Phosphate), ONPG (o-nitrophenyl- ⁇ -D- galactopyranoside).
- Useful enzymes include, without limitation, horseradish peroxidase and alkaline phosphatase.
- the incubation solution used to form the reagent zone also contains inert proteins, such as bovine serum albumin (BSA); and a non-ionic detergent, such as Tween-20®.
- BSA bovine serum albumin
- Tween-20® a non-ionic detergent
- the incubation solution can include other components, such as casein, gelatin, nonfat dry milk, ovalbumin, polyvinyl pyrrolidone, polyvinyl alcohol, or animal serum components including bovine IgG, murine IgG, and goat IgG, to improve the usability and performance of the device of the invention.
- the particular components, in addition to the incubation and detection antibodies, used in the incubation solution and their concentrations vary depending on the antigen being tested and the experimental conditions of the assay.
- the components are preferably chosen based on results of empirical test experiments.
- the components are selected to optimize the results obtained with the device of the invention, for example, components are preferably chosen to increase the intensity and contrast of antigen specific staining, and minimize background staining, thereby optimizing the signal to noise ratio of the device of the invention.
- the incubation solution is prepared by mixing the foregoing components in a buffer solution, such as phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- the reagent zone is generated by placing a volume (e.g., 10 ⁇ l) of the incubation solution onto the membrane strip near one end, and allowing the incubation solution to dry for transport and/or storage before use. Due to the presence of reagents, such as the inert proteins and Tween-20, the incubation and detection antibodies become soluble to facilitate diffusion of the antibody/antigen complexes to the sequentially arranged reaction zones as the membrane becomes wet during the course of the assay.
- Pharmaceutical Compositions Compositions comprising at least one anti-SARS CoV-22E8 antibody are also described herein.
- the composition comprises at least one anti- SARS CoV-22E8 antibody or antibody fragment that binds a spike protein epitope having the residue N501, as described herein, and at least one pharmaceutically acceptable carrier.
- the composition may further comprise at least one other therapeutic compound for the inhibition, treatment, and/or prevention of COVID-19.
- at least one other therapeutic compound may be contained within a separate composition(s) with at least one pharmaceutically acceptable carrier.
- kits comprising a first composition comprising at least one anti-SARS CoV-2 antibody or antibody fragment and a second composition comprising at least one other therapeutic compound for the inhibition, treatment, and/or prevention of COVID-19, as known in the art, and further described herein.
- the first and second compositions may further comprise at least one pharmaceutically acceptable carrier.
- the compositions of the instant invention are useful for treating autoantibody related diseases or disorders.
- a therapeutically effective amount of the composition may be administered to the subject.
- the dosages, methods, and times of administration are readily determinable by persons skilled in the art, given the teachings provided herein.
- a pharmaceutical composition for the treatment of COVID-19 comprises at least one antibody or epitope-binding fragment as described above and a pharmaceutically acceptable carrier.
- the composition contains one or more antibodies, as described above.
- the composition contains a fragment or other of the above-noted modifications of one or more of these antibodies.
- the pharmaceutical composition comprises one of more of a heavy chain variable domain sequence of SEQ ID NOs: 14, or a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identity to one of the sequences; or having a light chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 21, or combinations thereof.
- Other pharmaceutical compositions can be generated by use of the corresponding chain encoding nucleotide sequences SEQ ID NOs: 8 and 1, or sequences having at least 80, 85, 90, 95 or 99% identity thereto, e.g., for delivery in vectors, viruses and the like.
- compositions contain a mixture of two or more of the antibodies or epitope binding antibody fragments as described above and a pharmaceutically acceptable carrier.
- the antibodies, fragments or modifications are present in an amount effective to bind a SARS-CoV-2 variant having an N501 residue and neutralize or inhibit the effect of the virus.
- the composition contains a fragment or other of the above- noted modifications of one or more of these antibodies.
- the pharmaceutical composition comprises one of more of a heavy chain variable domain sequence identified herein, one of more of a light chain variable domain sequence identified herein, or a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to one of these sequences, or a fragment or modification thereof.
- Suitable pharmaceutical carriers or excipients for such compositions include, without limitation, the diluent, adjuvant, excipient, auxiliary agent, carrier or vehicle with which an antibody, fragment or modification thereof is administered, as described above.
- Methods of Treatment The compositions comprising these anti-SARS-CoV-2 spike variant with N501 antibodies may be used in methods for the inhibition, prevention, and/or treatment of COVID-19.
- the methods comprise administering at least one anti-SARS-CoV-2 antibody to a subject.
- the methods of the instant invention may further comprise the administration of at least one other therapeutic for COVID-19.
- the anti-SARS-CoV-2 antibodies may be co-administered with an anti-inflammatory agent and/or immunosuppressant.
- the agents administered to the subject may be contained within a composition comprising at least one pharmaceutically acceptable carrier.
- the agents may be administered consecutively (before or after) and/or at the same time (concurrently).
- the agents may be administered in the same composition or in separate compositions.
- the methods (and compositions) described herein comprise administering at least one antibody or antibody fragment which is immunologically specific for SARS-CoV-2 spike protein with N501 (anti-SARS-CoV-2 antibody) to a subject.
- the anti-SARS-CoV-2 antibody is immunologically specific for SARS-CoV-2 spike protein with N501 to the exclusion of SARS-CoV-2 spike protein with N501Y.
- the antibodies, fragments and modifications of the anti-SARS-CoV-2 antibody described herein are useful in methods for treating COVID-19, that comprises administering an effective amount of a single antibody or epitope binding fragment or a mixture of antibodies or fragments.
- a method for treating a subject suspected of having COVID-19 comprises administering an effective amount of a single antibody or epitope binding fragment or a mixture of antibodies or fragments as described herein.
- a method for treating a subject with such a disease comprises administering an effective amount of a single antibody or epitope binding fragment or a mixture of antibodies or fragments as described herein.
- the antibody comprises antibody 2E8 or fragments or modifications thereof.
- the antibody comprises any of the heavy chain sequences of SEQ ID NOs: 14, an epitope binding fragment or a modification thereof.
- the antibody comprises any of the light chain sequences of SEQ ID NOs: 21, an epitope binding fragment or a modification thereof.
- the antibody and antibody fragment may comprise at least one domain from the 2E8 monoclonal antibody described herein. See FIG.8A and FIG.8B and Table 1 for the sequences of the heavy, chain, light chains, CDRs, framework regions, and encoding nucleic acid sequence of these above referenced antibodies. These exemplified sequences can be used to generate the same antibodies or modifications or fragments thereof.
- the antibody or antibody fragment may comprise at least one, two, three, four, five, or all six complementarity-determining region (CDR) domains of the 2E8 monoclonal antibodies.
- the antibody or antibody fragment may comprise CDRs from these antibodies.
- the antibody or antibody fragment comprises at least one or both of the CDR3 domains.
- the domains of the antibody or antibody fragment have at least 90%, 95%, 97%, 99%, or 100% homology or identity with the domains present in the anti-human IDO2 antibodies or modifications as discussed above.
- Suitable routes of administering the antibody compositions described herein e.g., human monoclonal antibodies, multi-specific and bispecific molecules and immune- conjugates, fragments or modifications
- the antibody compositions can be administered by injection (e.g., intravenous or subcutaneous). Suitable dosages of the molecules used will depend on the age and weight of the subject and the concentration and/or formulation of the antibody composition.
- therapeutic formulations will generally be distinguished from other formulations in that they are substantially pyrogen free, or at least contain no more than acceptable levels of pyrogen as determined by the appropriate regulatory agency (e.g., FDA).
- Therapeutic compositions may be administered with a pharmaceutically acceptable diluent, carrier, or excipient, in unit dosage form. Administration may be parenteral (e.g., intravenous, subcutaneous), oral, or topical, or intravenous, or by inhalation, as non-limiting examples.
- any gene therapy technique using nucleic acids encoding the polypeptides of the invention, may be employed, such as naked DNA delivery, recombinant genes and vectors, cell-based delivery, including ex vivo manipulation of patients' cells, and the like.
- concentration of the compound in the formulation varies depending upon a number of factors, including the dosage of the drug to be administered, and the route of administration.
- the antibodies as described herein will generally be administered to a patient as a pharmaceutical preparation.
- patient refers to human or animal subjects. These antibodies may be employed therapeutically, under the guidance of a physician for the treatment of the indicated disease or disorder.
- the pharmaceutical preparation comprising the antibody molecules of the invention may be conveniently formulated for administration with an acceptable medium (e.g., pharmaceutically acceptable carrier) such as water, buffered saline, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), dimethyl sulfoxide (DMSO), oils, detergents, suspending agents or suitable mixtures thereof.
- an acceptable medium e.g., pharmaceutically acceptable carrier
- a pharmaceutically acceptable carrier such as water, buffered saline, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), dimethyl sulfoxide (DMSO), oils, detergents, suspending agents or suitable mixtures thereof.
- concentration of the agents in the chosen medium may be varied and the medium may be chosen based on the desired route of administration of the pharmaceutical preparation. Except insofar as any conventional media or agent is incompatible with the agents to be administered, its use in the pharmaceutical preparation is contemplate
- the dose and dosage regimen of an antibody according to the invention that is suitable for administration to a particular patient may be determined by a physician considering the patient's age, sex, weight, general medical condition, and the specific condition and severity thereof for which the antibody is being administered. The physician may also consider the route of administration of the antibody, the pharmaceutical carrier with which the antibody may be combined, and the antibody's biological activity. Selection of a suitable pharmaceutical preparation depends upon the method of administration chosen. For example, the antibodies of the invention may be administered by direct injection into any desired tissue or into the surrounding area. In this instance, a pharmaceutical preparation comprises the antibody molecules dispersed in a medium that is compatible with the target tissue.
- Antibodies may also be administered parenterally, by intravenous injection into the blood stream, or by subcutaneous, intramuscular or intraperitoneal injection.
- Pharmaceutical preparations for parenteral injection are known in the art. If parenteral injection is selected as a method for administering the antibodies, steps must be taken to ensure that sufficient amounts of the molecules reach their target cells to exert a biological effect.
- the lipophilicity of the antibodies, or the pharmaceutical preparation in which they are delivered may have to be increased so that the molecules can arrive at their target locations.
- the antibodies may have to be delivered in a cell-targeting carrier so that sufficient numbers of molecules will reach the target cells. Methods for increasing the lipophilicity of a molecule are known in the art.
- a small form of the antibody is to be administered, including but not limited to a Fab fragment, a Dab, an scFv or a diabody, it may be conjugated to a second (carrier) molecule such as, but not limited to polyethylene glycol (PEG) or an albumin-binding antibody or peptide to prolong its retention in O blood.
- a second (carrier) molecule such as, but not limited to polyethylene glycol (PEG) or an albumin-binding antibody or peptide to prolong its retention in O blood.
- PEG polyethylene glycol
- Pharmaceutical compositions containing an antibody of the present invention as the active ingredient in intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical compounding techniques.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral.
- any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques.
- the carrier will usually comprise sterile water, though other ingredients, for example, to aid solubility or for preservative purposes, may be included.
- injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
- a pharmaceutical preparation of the invention may be formulated in dosage unit form for ease of administration and uniformity of dosage.
- Dosage unit form refers to a physically discrete unit of the pharmaceutical preparation appropriate for the patient undergoing treatment. Each dosage should contain a quantity of active ingredient calculated to produce the desired effect in association with the selected pharmaceutical carrier. Procedures for determining the appropriate dosage unit are well known to those skilled in the art. Dosage units may be proportionately increased or decreased based on the weight of the patient.
- Appropriate concentrations for alleviation of a particular pathological condition may be determined by dosage concentration curve calculations, as known in the art.
- the appropriate dosage unit for the administration of anti-SARS-CoV-2 antibody molecules may be determined by evaluating the toxicity of the antibody molecules in animal models.
- Various concentrations of antibody pharmaceutical preparations may be administered to murine models of the disease or disorder and the minimal and maximal dosages may be determined based on the results and side effects as a result of the treatment.
- Appropriate dosage unit may also be determined by assessing the efficacy of the antibody molecule treatment in combination with other standard drugs.
- the dosage units of anti-SARS-CoV-2 antibody molecules may be determined individually or in combination with another treatment.
- the pharmaceutical preparation comprising the anti-SARS-CoV-2 antibody molecules may be administered at appropriate intervals, for example, at least twice a day or more until the pathological symptoms are reduced or alleviated, after which the dosage may be reduced to a maintenance level.
- the appropriate interval in a particular case would normally depend on the condition of the patient.
- the methods of the instant invention may further comprise monitoring the disease or disorder in the subject after administration of the composition(s) described herein to monitor the efficacy of the method.
- a patient with an active infection of SARS-CoV-2 or a patient with COVID-19 receives a treatment comprising at least one of the antibodies described herein in addition to an antiviral therapy, such as molnupiravir (Merck & Co., Inc. and Ridgeback Biotherapeutics) or remdesivir (Gilead Sciences, Inc.).
- an antiviral therapy such as molnupiravir (Merck & Co., Inc. and Ridgeback Biotherapeutics) or remdesivir (Gilead Sciences, Inc.).
- a patient with an active infection of SARS-CoV-2 or COVID-19 receives a treatment comprising at least one of the antibodies described herein in addition to at least one anti-inflammatory agent, such as tocilizumab (Genentech USA, Inc.) and lenzilumab (Humanigen, Inc.).
- a patient with an active infection of SARS-CoV- 2 or COVID-19 receives a treatment comprising at least one of the antibodies described herein in addition to at least one steroid, such as glucocorticosteroids, methylprednisolone, and dexamethasone.
- anti-inflammatory agents include, without limitation, non- steroidal anti-inflammatory drugs (NSAIDs; e.g., aspirin, ibuprofen, naproxen, methyl salicylate, diflunisal, indomethacin, sulindac, diclofenac, ketoprofen, ketorolac, carprofen, fenoprofen, mefenamic acid, piroxicam, meloxicam, methotrexate, celecoxib, valdecoxib, parecoxib, etoricoxib, and nimesulide ), corticosteroids (e.g., prednisone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, tramcinolone, and fluticasone), rapamycin, acetaminophen, glucocorticoids, steroids, beta- agonists,
- a patient with an active infection of SARS-CoV-2 or COVID-19 receives a treatment comprising at least one of the antibodies described herein in addition to at least one of the following: convalescent plasma or serum, intravenous immunoglobulins, eculizumab, heparin or another anticoagulant, angiotensin-converting enzyme (ACE) inhibitors, vitamin C, vitamin D, zinc, or n-acetylcysteine.
- ACE angiotensin-converting enzyme
- a patient diagnosed with a SARS-CoV-2 infection or COVID-19 using the methods described herein receives a treatment comprising at least one of an antiviral therapy, such as molnupiravir (Merck & Co., Inc.
- remdesivir Gilead Sciences, Inc.
- a neutralizing monoclonal antibody that targets SARS- CoV-2 such as sotrovimab (GlaxoSmithKline plc.), bamlanivimab (Eli Lilly and Co.), etesevimab (Eli Lilly and Co.), casirivimab (Regeneron Pharmaceuticals Inc.), and imdevimab (Regeneron Pharmaceuticals Inc.).
- an anti-inflammatory agent such as tocilizumab (Genentech USA, Inc.) and lenzilumab (Humanigen, Inc.
- a steroid such as glucocorticosteroids, methylprednisolone, and dexamethasone.
- NSAIDs non-steroidal anti-inflammatory drugs
- NSAIDs non-steroidal anti-inflammatory drugs
- ibuprofen e.g., aspirin, ibuprofen, naproxen, methyl salicylate, diflunisal, indomethacin, sulindac, diclofenac, ketoprofen, ketorolac, carprofen, fenoprofen, mefenamic acid, piroxicam, meloxicam, methotrexate, celecoxib, valdecoxib, parecoxib, etoricoxib, and nimesulide ), corticosteroids (e.g., prednisone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, tramcinolone, and fluticasone), rapamycin, acetaminophen, glucocor
- a patient with an active infection of SARS-CoV-2 or COVID-19 receives a treatment comprising at least one of the following: convalescent plasma or serum, intravenous immunoglobulins, eculizumab, heparin or another anticoagulant, angiotensin-converting enzyme (ACE) inhibitors, vitamin C, vitamin D, zinc, or n-acetylcysteine.
- ACE angiotensin-converting enzyme
- a human mAb that binds N501 but not Y501 and can thus distinguish delta from other VBMs in an ELISA or other diagnostic assay. Furthermore, among the Y501-containing VOCs, the previously described human mAb CB6 binds alpha and gamma, but not beta. Diagnostic assays incorporating these two mAbs are useful for variant-specific SARS-CoV-2 POC testing.
- the foundation of the present work is a pair of human mAbs (2E8 and CB6) that differentially recognize SARS-CoV-2 VOCs and VOIs in an ELISA.
- VOCs and VOIs have acquired mutations in their spike glycoprotein, which mediates receptor binding and is one of the major targets of the adaptive immune response to SARS-CoV-2.
- RBD receptor binding domain
- both mAbs bind to B.1.427, B.1.429, and B.1.617. When used together, these two mAbs discriminate between clinically important SARS-CoV-2 VOCs and VBMs.
- the 2E8 mAb was cloned from a male in his 50s who had a confirmed case of COVID-19 contracted in New York City in March 2020. A peripheral blood sample was obtained 42 days after his first symptom.
- the 2E8 mAb was cloned using the human hybridoma method described previously [36].
- VSV-G:S1 particles pseudotyped with the SARS-CoV-2 spike protein S1 domain
- S1 trimer a trimeric, S1 protein
- the 2E8 bound all four S1 antigens, with somewhat less binding to the VSV-G:S1 and the S1 trimer at the 0.1 ⁇ g/mL level (FIG. 1A).
- RVP reporter viral particle
- the full immobilization sequence of the SARS-CoV-2 S1 domain and 2E8 binding to the immobilized S1 domain are shown in FIG.6 and FIG.7A – FIG.7C, respectively.
- CB6 is a well characterized, potent neutralizing mAb that shows reduced neutralization activity against many VBMs.
- CB6 shows no binding to beta and reduced binding to gamma but no reduction in binding to alpha, delta, kappa, or epsilon (FIG.3B).
- K417N by itself significantly reduces binding (FIG. 3B). This is consistent with the observations of others [45] and suggests that CB6 is useful to differentiate N501Y-containing variants alpha and gamma from beta in an ELISA.
- Example 3 Spike variant binding in a sandwich ELISA Sandwich ELISAs can be used to evaluate mAbs for use in LFAs, as both formats use a pair of non-overlapping mAbs for antigen capture and detection.
- the mAbs were used to capture the spike antigens, which were then detected with the biotinylated murine mAb (FIG. 4A).
- CB6 can be used in this format to differentiate Y501-containing VBMs alpha and gamma from beta.
- Table 5 Antibody binding in sandwich ELISAs to SARS-CoV-2 variants The emergence of SARS-CoV-2 variants has greatly complicated the efforts to control and treat the disease. The variants differ in their ability to evade antibody immunity provided by vaccination or passive immunization and, therefore, may dramatically impact health care facilities, congregate housing settings, public transportation hubs, and high-risk occupational environments. Variant-specific POC testing is necessary to protect individuals in these settings, as well as to screen populations for shifts in SARS-CoV-2 epidemiology.
- N501Y meta-signature variants As the delta variant is currently the dominant strain globally, an Ag-RDT to detect infections with N501Y meta-signature variants will be a powerful tool for disease monitoring and control.
- the N501 residue lies on the “right shoulder” of the RBD and directly interacts with ACE2 during cell binding [11,12].
- the N501Y mutation does not dramatically alter the overall RBD structure. This suggests that 2E8 binds N501 and/or may be sterically inhibited by Y501.
- the 2E8 binding site overlaps the CB6 site, yet its binding is not affected by changes at K417, and CB6 binding is largely insensitive to the N501Y change [12].
- 2E8 has ⁇ 100-fold less neutralizing activity than that of CB6, even though its affinity is only 3-fold lower than that of the CB6 (7.38 ⁇ 0.58 nM vs.2.49 ⁇ 1.65 nM) [32].
- CB6 interaction with the spike has been defined using X-ray crystallography [32].
- CB6 is a type I neutralizing mAb that contacts the K417 and N501 residues.
- CB6 neutralization is unaffected by the N501Y RBD mutation, consistent with the relative unimportance of this residue to CB6 binding.
- the gamma and beta variant changes essentially eliminate CB6 binding and neutralization [46,47,48].
- the 2E8 mAb would be used in a multiplexed assay in parallel with a mAb or ACE2 reagents capable of binding all variants [49,50,51].
- Such tests can be an important adjunct to NAATs, as they are ideal for POC testing to protect vulnerable populations and broaden epidemiological surveillance.
- Both 2E8 and CB6 have immediate applicability for testing while delta is the most prevalent variant.
- additional mAbs will be needed as the variant landscape evolves. This objective should be achievable, as the repertoire of potential variant-specific mutations is well-defined, a large number of anti-spike mAbs have been cloned, and extensive structural data describing mAb–spike interactions have been generated.
- Example 4 Materials and Methods SARS-CoV-2 spike antigens and antibodies
- a Wuhan-Hu-1 SARS-CoV-2 spike protein cDNA was cloned into the XhoI and NheI sites of a modified recombinant VSV vector containing an additional transcription start/stop signal between the G and L genes.
- the recombinant virus was recovered on 293T cells as described previously [33] and filtered through 0.22 ⁇ m PVDF filters (MilliporeSigma, Burlington, MA, USA)). The filtered virus was then used to inoculate human BEAS-2B lung cells (gift from R. Plemper, University of Georgia) seeded in Cellstack culture chambers (Corning, Corning, NY, USA).
- the infected cells were cultured in serum-free Optipro medium (Invitrogen, Waltham, MA, USA). Cell culture supernatant was harvested three days post-inoculation, clarified by centrifugation at 3000 g, and filtered through 0.45 ⁇ m PES membrane filters (Nalgene, Rochester, NY, USA). The filtered supernatant was layered on 20% sucrose in DPBS, and particles were sedimented by ultracentrifugation in a SW32 rotor (Beckman, Brea, CA, USA) for 1.5 h at 25,000 rpm. Viral particles were resuspended in phosphate-buffered saline and inactivated with 0.05% beta-propiolactone (BPL).
- BPL beta-propiolactone
- the particles were incubated at 37 °C for 45 min to hydrolyze BPL and filtered through 0.22 ⁇ m PES filters (MilliporeSigma).
- 2% beta-octyl-glucopyranoside (OGP) was added to the viral particles. After 15 min incubation at room temperature, the mixture was centrifuged for 1.5 h in a SW55 rotor (Beckman) at 45,000 rpm. After centrifugation, the supernatant was collected and filtered through 0.22 ⁇ m PES filters.
- the fusion protein included residues G283-F718 (eliminating the S1 amino terminal domain and extending to the S1–S2 boundary) and a mutated furin cleavage site.
- the fusion protein included a mu-phosphatase signal peptide (N- terminal) and a C-terminal fibritin T4 trimerization domain, followed by a Myc site and a 6XHis tag.
- a gene encoding this fusion protein was produced by Twist Bioscience (South San Francisco, CA, USA) and cloned into the pTwist CMV BetaGlobin expression vector.
- the construct was transiently transfected into Expi-293F cells (Thermo Fisher) following the manufacturer’s instructions. Due to limited secretion of the protein, on Day 5, we pelleted the cells by centrifugation at 3000 rpm at 4 °C for 20 min. The pellet was resuspended in Takara xTractorTM buffer (Takara Bio, Mountain View, CA, USA) with GenDEPOT Protease Inhibitor Cocktail II, EDTA Free (10X) (Thermo Fisher), incubated on ice with intermittent mixing for 15 min, and then centrifuged at 3500 rpm for 15 min at 4 °C.
- the supernatant was filtered through a 0.45 ⁇ m filter, and the protein was isolated with a CapturemTM His-Tagged Purification Column (Takara).
- the purity and integrity of S1 trimer were assessed by SDS:PAGE (data not shown) and Western blot (FIG.5) and detected with the Anti-6X His tag® antibody [HIS.H8] (Cat: ab18184; Abcam, Cambridge, MA, USA) and Peroxidase AffiniPure Goat Anti-Mouse IgG, Fc ⁇ fragment specific (RRID: AB_2313585, Jackson ImmunoResearch, West Grove, PA, USA).
- a recombinant S1 fragment trimer (S1-trimer): We also expressed a SARS-CoV-2 S1 domain fragment as a trimeric protein in Expi-293F cells, in part following [32] (FIG.5).
- the fusion protein included a mu-phosphatase signal peptide (N-terminal) and a C-terminal fibritin T4 trimerization domain, followed by a Myc site and a 6XHis tag.
- a gene encoding this fusion protein was synthesized by Twist Bioscience (South San Francisco, CA) and cloned into the pTwist CMV Beta Globin expression vector.
- the construct was transiently transfected into Expi-293F cells (Thermo Fisher Scientific, Waltham, MA) following the manufacturer’s instructions. Due to limited secretion of the protein, on Day 5 we pelleted the cells by centrifugation at 3000 rpm at 4 °C for 20 minutes.
- the pellet was resuspended in Takara xTractorTM buffer (Takara Bio, USA, Mountain View, CA) with GenDEPOT Protease Inhibitor Cocktail II, EDTA Free (10X) (Thermo Fisher), incubated on ice with intermittent mixing for 15 minutes, then centrifuged at 3500rpm for 15 minutes at 4 °C. The supernatant was filtered through a 0.45 ⁇ m filter and protein was isolated with a CapturemTM His-Tagged Purification Column (Takara).
- S1-F-trimer The purity and integrity of S1-F-trimer was assessed by SDS:PAGE (data not shown) and Western blot (FIG.5), and was detected with the Anti-6X His tag® antibody [HIS.H8] (Cat: ab18184; Abcam, Cambridge, MA) and Peroxidase AffiniPure Goat Anti-Mouse IgG, Fc ⁇ fragment specific (RRID: AB_2313585, Jackson ImmunoResearch, West Grove, PA).
- Anti-6X His tag® antibody Cat: ab18184; Abcam, Cambridge, MA
- RRID Peroxidase AffiniPure Goat Anti-Mouse IgG, Fc ⁇ fragment specific
- Example 5 2E8 monoclonal antibody isolation
- PBMCs peripheral blood mononuclear cells
- All subjects provided signed informed consent under a protocol approved by the Main Line Hospitals Institutional Review Board.
- VSV G:S1 pseudotyped VSV (VSV G:S1) particles by ELISA.
- a male volunteer in his 50s was found to have anti-spike titers >1:8000. He was a Caucasian, without comorbid health conditions, diagnosed by RT-PCR testing in New York City in March 2020. He required hospitalization due to respiratory decompensation but was not intubated.
- the 6A control mAb was also produced from its hybridoma [37].
- the 2E8 Ig variable domains were amplified by RT-PCR, using the Qiagen RNA extraction kit (Cat: 74124; Qiagen, Germantown, MD, USA), and reverse transcribed with the Omniscript RT Kit (Cat: 205111; Qiagen).
- Variable domain cDNA sequences were amplified with consensus primer sets specific for human immunoglobulin heavy and light chain genes [38]. Amplified sequences were isolated by agarose gel electrophoresis, purified with the QiaQuick Gel Extraction kit (Cat: 28706; Qiagen), sequenced by Psomagen, Inc.
- the assays were performed at 21 °C with buffer PBS 0.05% Tween-20 (PBST).
- the S1 protein (Wuhan-Hu-1 S1 (L): SARS-CoV-2 (2019-nCoV) Spike S1-His Recombinant Protein (Cat: 40591-V08H)) was immobilized on a nitrilotriacetic acid (NTA) sensor chip following EDTA conditioning. His-streptavidin (Abcam, Cat: ab78833) was immobilized in the reference channel as a control ligand.
- NTA nitrilotriacetic acid
- Purified recombinant 2E8 mAb was diluted in PBST supplemented with 0.1% BSA and injected for 5 min at a flow rate of 20 ⁇ L/min in a concentration series from 1.23 nM to 100 nM, with 10 min dissociation time. Sensors were regenerated with two injections of 500mM imidazole per regeneration step, with 40 s contact time and 270 s dissociation time. Sensorgrams were fitted with Trace Drawer analysis software (Ridgeview Instruments, Uppsala, Sweden).
- ELISAs Recombinant antibody binding to SARS-CoV-2 spike antigens: Recombinant antibody binding to SARS-CoV-2 spike antigens: NUNC high-binding ELISA plates (Thermo Fisher) were coated in PBS with 500 ng/well antigen at 4 °C overnight. Plates were washed three times with PBS containing 0.05% Tween-20 (PBST) and blocked with blocking buffer (BB) (PBST containing 5% non-fat dry milk) at 37 °C for one hour. Ten-fold serial dilutions of the mAbs were diluted in BB, added in triplicate, and incubated for 1 h at 37 °C.
- PBST PBS containing 0.05% Tween-20
- BB blocking buffer
- HRP horseradish peroxidase
- RRID AB_2687484 mouse anti-human IgG Fc fragment specific secondary antibody
- the mouse mAb positive control was SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody (RRID:AB_2857934; Sino Biological) and was detected with Goat Anti-Mouse Ig, Human ads-HRP (Cat: 1010-05; Southern Biotech).
- Sandwich ELISAs for specific variant binding Sandwich ELISAs for specific variant binding: NUNC high-binding ELISA plates were coated with 100 ng/well 2E8 or CB6 or 500 ng/well anti-6X His tag® antibody [HIS.H8] (RRID:AB_444306; Abcam), in PBS overnight at 4 °C. Plates were washed and blocked as above.
- Example 7 Flow cytometry-based receptor-binding inhibition assay Antibody interference of S1 binding to human ACE2 receptor on the cell surface of 293T cells was measured by flow cytometry. Briefly, 0.1 ⁇ g/mL biotinylated SARS-CoV-2 spike S1 (Cat: 40591-V08H-B; Sino Biological) was incubated with 1 ⁇ g/mL recombinant mAb or a human ACE2-Fc fusion protein (Cat fc-hace2: Invivogen, San Diego, CA, USA) at 37 oC for one hour.
- biotinylated SARS-CoV-2 spike S1 Cat: 40591-V08H-B; Sino Biological
- 1 ⁇ g/mL recombinant mAb or a human ACE2-Fc fusion protein Cat fc-hace2: Invivogen, San Diego, CA, USA
- the S1:mAb mixtures were added to 5 ⁇ 105293T-hsACE2 cells (Cat: C-HA101; Integral Molecular) and incubated for 30 min at room temperature. Following incubation, cells were washed twice with PBS containing 2% fetal bovine serum (PBSF) and incubated with Alexa Flour 488 Streptavidin (RRID: AB_2337249; Jackson ImmunoResearch) (1:200 dilution) to detect S1 binding and Goat Anti-Human IgG (H + L) Antibody, Alexa Fluor 647 Conjugated (RRID:AB_2535862; Thermo Fisher) to detect human IgG binding.
- PBSF fetal bovine serum
- Alexa Flour 488 Streptavidin RRID: AB_2337249; Jackson ImmunoResearch
- Example 8 Pseudotyped SARS-CoV-2 antibody neutralization assay
- the antibody neutralization assay was obtained from Integral Molecular and performed following their protocol, using the 293T-hsACE2 cell line (Cat: C-HA101; Integral Molecular, Philadelphia, PA, USA) and the pseudotyped SARS-CoV-2 (Wuhan-Hu- 1 strain) reporter viral particles (RVPs) with luciferase (Cat: RVP-701L, Lot CL-114B, Integral Molecular). Briefly, in a 96-well plate, 5-fold serially diluted mAbs were combined with 10 ⁇ L RVPs and incubated for 1 h at 37 °C.
- Example 9 Epitope binning We performed competitive binding assays to test whether biotinylated 2E8 could bind SARS-CoV-2 spike antigens (S1 and RBD) in the presence of the human mAbs CB6, CR3022, and the murine SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody (RRID:AB_2857934; Sino Biological) [43,44].
- Black NUNC MaxiSorP 96-well plates (Thermo Fisher) were incubated overnight with 500 ng/well S1 or RBD, then washed three times with PBST, and blocked with BB for 1 h at 37 °C.
- the 2E8 was biotinylated with the EZ-Link Sulfo-NHS-Biotin kit (Thermo Fisher), and the S1 and sRBD antigen binding curves were found to be linear between 2.5 pg/mL and 2.5 ⁇ g/mL.
- 500 ng/well of the competing mAb was added to half of the antigen wells and PBS to the other half and then incubated for 1 h at 37 °C, followed by 3 PBST washes.
- Adekar S.P. Jones R.M., Elias M.D., Al-Saleem F.H., Root M.J., Simpson L.L., Dessain S.K.
- IMGT/V-QUEST IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences.
- IG immunoglobulin
- TR T cell receptor
- Puligedda R.D. Kouiavskaia D., Al-Saleem F.H., Kattala C.D., Nabi U., Yaqoob H., Bhagavathula V.S., Sharma R., Chumakov K., Dessain S.K. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes. Vaccine.2017;35:5455– 5462. doi: 10.1016/j.vaccine.2017.03.038. 45. Wang R., Zhang Q., Ge J., Ren W., Zhang R., Lan J., Ju B., Su B., Yu F., Chen P., et al.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
Provided herein are antibodies and compositions as well as methods for utilizing the same. The methods include diagnosing a subject as being infected with a SARS-CoV-2 virus by contacting a sample obtained from the subject with an antibody that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Wuhan SI protein variant at N501, but does not bind a SARS-CoV-2 SI protein variant that has a spike protein mutation N501 Y, to form an antib ody/SARS -Co V-2 virus complex when the antigen is present in the sample. The subject is diagnosed as being infected with a SARS-CoV-2 virus variant having the residue N501 and not N501 Y when the antibody/SARS-CoV-2 virus complex is detected.
Description
METHODS AND COMPOSITIONS INCLUDING NOVEL ANTIBODIES FOR DIAGNOSING COVID-19 VARIANTS INCORPORATION-BY REFERENCE OF MATERIAL SUBMITTED IN ELECTRONIC FORM Applicant hereby incorporates by reference the Sequence Listing material filed in electronic form herewith. This .xml file is labeled “MLH-130.PCT”, was created on October 7, 2022, and is 38.0 KB (38,919 bytes) in size. BACKGROUND OF THE INVENTION Efforts to control SARS-CoV-2 have been challenged by the emergence of variant strains that have important implications for clinical and epidemiological decision making. These variants arise through error-prone genome replication and the outgrowth of strains with mutations that provide a selective advantage. The CDC has designated four of these strains Variants of Concern (VOCs): B.1.1.7 (alpha, United Kingdom), B.1.351 (beta, South Africa), P.1 (gamma, Brazil), and B.1.617.2 (delta, India). VOCs can evade antibody immunity, whether provided by vaccination or passive immunization with monoclonal antibodies (mAbs). VOCs are also more transmissible than earlier strains and therefore warrant enhanced mitigation practices. The VOCs pose a particular risk to health care facilities, congregate housing settings, public transportation hubs, and high-risk occupational environments. As multiple VOCs can circulate simultaneously within a population, variant- specific point-of-care testing (POC) is necessary to effectively diagnose and manage SARS- CoV-2 infections, as well as to monitor for changes in SARS-CoV-2 variant epidemiology. The VOCs can be distinguished by amino acid changes in the spike protein receptor binding domain (RBD), which mediates receptor binding and is one of the major targets of the SARS-CoV-2 neutralizing antibody response. Five RBD residues have undergone changes in the VOCs: K417, L452, T478, E484, and N501. One of the most common is the N501Y substitution, which occurs in the alpha, beta, and gamma VOCs. The N501 residue lies on the “right shoulder” of the RBD, where it directly contacts the ACE2 receptor through hydrophobic interactions. N501Y has arisen simultaneously in many lineages and confers a selective advantage over Wuhan-Hu-1 (L) by increasing the affinity of the RBD for the ACE2 receptor 3- to 16-fold. An RBD mutation screen for high affinity ACE2 binding repeatedly produced de novo N501Y mutants, consistent with the worldwide appearance of multiple independent N501Y-containing variants. N501Y collaborates with other RBD
mutations to increase binding and infectivity (e.g. E484K), and structural and functional studies suggest that N501Y will continue to circulate among SARS-CoV-2 variants via co- selection with mutations that resist antibody neutralization. A recent example is the mu (B.1.621) Variant of Interest (VOI), which has spread worldwide spread since its identification in Colombia in January 2021 and is relatively resistant to vaccine immunity and some mAb therapeutics. Mu contains the RBD mutations R346K, E484K, and N501Y. N501Y has originated many times globally and is positively selected because it allows tyrosine side-chain interactions that increase infectivity through enhanced ACE2 binding. Mutagenesis and modeling experiments suggest that N501Y will be a feature of important variants likely to arise in the future, contributing to the spread of variants resistant to current anti-viral vaccines and therapeutics. Variant testing generally relies on Nucleic Acid Amplification Tests (NAATs) such as DNA sequencing, S-Gene Target Failure (SGTF), multiplex PCR, or CRISPR. However, these generally take too long for efficient POC use and require specialized laboratories. Immunoassays that detect viral antigens, e.g., Antigen-detection Rapid Diagnostic Tests (Ag- RDTs), are better suited to POC testing. Ag-RDTs are typically lateral flow assays (LFAs) that can be read within 15-30 minutes. They are less sensitive than NAATs, but they have high negative predictive values and are therefore ideal for POC testing, in which rapid turnaround time and high testing frequency are essential for pandemic control. At least twenty-five SARS-CoV-2 Ag-RDTs have been granted an Emergency Use Authorization by the FDA. However, variant-specific tests have not yet been implemented A continuing need in the art exists for new and effective tools and methods for identifying strain-specific infections and for treatment of the same. SUMMARY OF THE INVENTION Antibodies, compositions, and methods for diagnosing and treating COVID-19 variants are provided herein. In a first aspect, an antibody that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Wuhan S1 protein variant at N501, but does not bind a SARS-CoV-2 S1 protein variant that has a spike protein mutation N501Y is provided. In one embodiment, the antibody includes: (a) a heavy chain variable region (VH) comprising (i) a complementarity- determining region 1 (CDR1) of SEQ ID NO: 15, (ii) a complementarity-determining region 2 (CDR2) of SEQ ID NO: 17, and (iii) a complementarity-determining region 3 (CDR3) of SEQ ID NO: 18; and/or
(b) a light chain variable region (VL) comprising, (i) a CDR1 of SEQ ID NO: 22, (ii) a CDR2 having the amino acid sequence Asp-Asp-Ser (DDS), and (iii) a CDR3 of SEQ ID NO: 23. In certain embodiments, the antibody includes a VH having an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 14 and/or a VL having an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 21. In one embodiment, the antibody includes a VH comprising the amino acid sequence of SEQ ID NO: 14 and a VL comprising the amino acid sequence of SEQ ID NO: 21. In certain embodiments, the antibody is formatted as a non-human antibody, wherein the VH has CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 15, 17, and 18, respectively, and wherein the VL has CDR1, CDR2, and CDR3 sequences of SEQ ID NO: 22, amino acid sequence DDS and SEQ ID NO: 23, respectively. In another aspect, a method of diagnosing a subject as being infected with a SARS- CoV-2 virus or screening a subject for a SARS-CoV-2 infection is provided. The method includes contacting a sample obtained from the subject with at least one antibody or a panel of antibodies that bind selected S1 antigens in SARS-CoV-2 variants to form an antibody/SARS-CoV-2 virus complex when the antigen is present in the sample. One antibody in the panel of antibodies is an antibody as described herein that binds S1 antigens having only residue N501, not mutations at that site. The method further includes detecting the pattern of binding between said antibodies by the presence or absence of an antibody/SARS-CoV-2 virus complex, and diagnosing the subject as being infected with a specific SARS-CoV-2 virus variant based upon the pattern of binding between the panel of antibodies and the viral S1 protein. In one embodiment, the test is an Antigen Diagnostic Test immunoassay directed to detect at pattern of spike RBD polymorphisms at S1 amino acid residues K417, L452, E484, and N501, wherein the pattern detected by the selected antibodies or antigen binding fragments thereof distinguishes among SARS-CoV-2 variant infections. In another aspect, a method of diagnosing a subject as being infected with a SARS- CoV-2 virus or screening a subject for a SARS-CoV-2 infection includes contacting a sample obtained from the subject with at least one antibody or a panel of antibodies that bind selected S1 antigens in SARS-CoV-2 variants to form an antibody/SARS-CoV-2 virus complex when the antigen is present in the sample. In another embodiment, the method includes contacting a sample obtained from the subject with an antibody that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Wuhan S1 protein variant at N501, but
does not bind a SARS-CoV-2 S1 protein variant that has a spike protein mutation N501Y, to form an antibody/SARS-CoV-2 virus complex when the antigen is present in the sample. The subject is diagnosed as being infected with a SARS-CoV-2 virus variant having the residue N501 and not N501Y, when the antibody/SARS-CoV-2 virus complex is detected. In one embodiment, the test further comprises a pan-SARS-CoV-2 specific antibody. In another aspect, a diagnostic composition is provided. The composition includes an antibody as described herein, conjugated to or associated with a detectable label. In yet another aspect, a transformed cell is provided, that expresses an antibody as described herein. In another aspect, a diagnostic kit for the diagnosis of a SARS-CoV-2 variant is provided. The diagnostic kit includes an antibody as described herein, conjugated to or associated with a detectable label. In certain embodiments, the kit includes a pan-SARS- CoV-2 specific antibody, conjugated to or associated with a detectable label. In another aspect, a pharmaceutical composition is provided. The composition includes an antibody as described herein, and a pharmaceutically acceptable carrier. In certain embodiments, the composition includes a second therapeutic agent. In yet another aspect, a method of preventing or treating a SARS-CoV-2 viral infection or COVID19 in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of the composition that includes an antibody as described herein. BRIEF DESCRIPTION OF THE DRAWINGS FIG.1A – FIG.1D show SARS-CoV-2 L strain (Wuhan-Hu-1) spike binding by the 2E8 human mAb. (FIG.1A) The 2E8 mAb binding in a direct ELISA to SARS-CoV-2 antigens: S1, S1 D614G, and nucleocapsid (Sino Biologicals); spike-pseudotyped VSV particles; and a recombinant S1 trimer. Samples were tested in triplicate. Error bars = S.E.M. (not visible due to minimal differences). (FIG.1B) S1 binding to 293T-hsACE2 cells in the presence of 2E8, 4G1 (isotype control IgG), CR3022, CB6, and an ACE2-Fc fusion protein was assessed by flow cytometry. S1 cell binding, x-axis; IgG binding, y-axis. (FIG.1C) Pseudovirus neutralization assay.293T-hsACE2 cells were transduced with SARS-CoV-2 luciferase (Wuhan-Hu-1 strain) reporter viral particles (RVPs) in the presence of the mAbs, 6A (isotype control IgG), CR3022, 2E8, and CB6, and a polyclonal IgG isolated from the 2E8 B cell donor (P24). Normalized percent infection is shown; samples were tested in
triplicate. Error bars = S.E.M. (FIG.1D) SPR analysis of 2E8 binding to the spike S1 domain, performed on the Nicoya OpenSPR™; KD = 7.38 ± 0.58 nM. FIG.2A – FIG.2D show epitope binning for 2E8 on the SARS-CoV-2 S1 and RBD. We performed competition binding assays to test 2E8 binding in the presence of the CR3022, CB6, and the murine anti-S1 mAb. L-type spike (FIG.2A, FIG.2C) or RBD (FIG.2B, FIG. 2D) was captured on the plate and binding of biotinylated 2E8, or the anti-spike murine mAb was tested in the presence of non-biotinylated competitor mAbs. FIG.3A – FIG.3C show differential recognition of SARS-CoV-2 variant spike antigen by direct ELISA. The 2E8 (FIG.3A), CB6 (FIG.3B), and the mouse anti-S1 mAb (FIG.3C) were tested for binding to spike antigens adhered to an ELISA plate: L RBD (Wuhan-Hu-1), α S1 (B.1.1.7), β S1 (B.1.351), γ S1 (P.1), δ RBD (B.1.617.2), K417N RBD, κ RBD (B.1.617.1), ε S1 (B.1.429). Error bars = S.E.M. FIG.4A – FIG.4B show differential recognition of SARS-CoV-2 variant spike antigens using a sandwich ELISA with human mAbs. The mAbs were adhered to the ELISA plate and tested for capture of soluble spike antigen. Bound antigen was detected with the mouse anti-S1 mAb. (FIG.4A) Both 2E8 and CB6 are compared (left and right columns, respectively, for each variant). (FIG.4B) An anti-His tag capture antibody was used as a positive control. Antigens used (same as FIG.3A – FIG.3C): L RBD (Wuhan-Hu-1), α S1 (B.1.1.7), β S1 (B.1.351), γ S1 (P.1), δ RBD (B.1.617.2), K417N RBD, κ RBD (B.1.617.1), ε S1 (B.1.429). FIG.5 shows a full immobilization sequence of the SARS-CoV-2 S1 domain. The antigen was adhered via a His-tag onto an NTA Sensor in Active (Channel 2). A control His- Streptavidin was used Reference Channel 1.20 ug/ml for each protein resulted in matching levels of ligand density on the sensor surface at the end of immobilization. FIG.6 shows anti-spike antibody 2E8 binding to the immobilized S1 domain. The initial non-specific binding (NSB) test on the NTA sensor is performed with PBST supplemented with 0.1% BSA to reduce non-specific binding. Decreasing concentrations are displayed, starting with the highest concentration at the top. FIG.7A – FIG.7C show pseudotyped VSV-G:S1 and S1 trimer antigens. (FIG.7A) SDS:PAGE demonstrating proteins contained in the VSV-G:S1 pseudotyped particles. Detergent-solubilized G:Sa protein is shown for comparison. (FIG.7B) SDS:PAGE of the S1 trimer, analyzed as reduced and non-reduced (NR) samples. (FIG.7C) Map of the gene encoding the S1 trimer.
FIG.8A and FIG.8B provide the heavy chain (FIG.8A; SEQ ID NO: 1) and light chain (FIG.8B; SEQ ID NO: 8) variable region sequences for the 2E8 mAb, including CDRs and framework regions. FIG.9A and FIG.9B provide an overview of a solid support diagnostic device having sequentially arranged reaction zones. DETAILED DESCRIPTION The present invention comprises antibodies, compositions, and methods useful for detection of specific SARS-CoV-2 variants by detecting variant specific antigens. The described antibodies are useful as a component of antigen-detection rapid diagnostic tests (Ag-RDTs) that can be used in point-of-care and repeat testing situations to diagnose active COVID-19 cases in 15-30 minutes. Described herein, in one embodiment is a monoclonal antibody, designated as 2E8, that specifically binds to SARS-CoV-2 spike protein that contain an aspargine at position 501 (N501) and does not bind to SARS-CoV-2 spike proteins that contain a common mutation that occurs in many variants of concern (N501Y). The mAb 2E8 is useful in compositions, methods, and kits to immediately detect cases of variants that contain the N501Y mutation within the current background of delta (B.1.617.2) global predominance. Twenty-five Ag- RDTs have been granted an EUA by the FDA. None of these are antigen specific. The mAbs described in the present invention could be adapted by these companies to produce variant- specific Ag-RDTs. Technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs and by reference to published texts, which provide one skilled in the art with a general guide to many of the terms used in the present application. The definitions contained in this specification are provided for clarity in describing the components and compositions herein and are not intended to limit the claimed invention. The terms “a” or “an” refers to one or more. For example, “an expression cassette” is understood to represent one or more such cassettes. As such, the terms “a” (or “an”), “one or more,” and “at least one” are used interchangeably herein. As used herein, the term “about” means a variability of plus or minus 10 % from the reference given, unless otherwise specified. The words “comprise”, “comprises”, and “comprising” are to be interpreted inclusively rather than exclusively, i.e., to include other unspecified components or process
steps. The words “consist”, “consisting”, and its variants, are to be interpreted exclusively, rather than inclusively, i.e., to exclude components or steps not specifically recited. An “antibody” or “antibody molecule” is any immunoglobulin, including antibodies and fragments thereof, that binds to a specific antigen. In one embodiment, antibody or antibody molecule contemplates intact immunoglobulin molecules, immunologically active portions of an immunoglobulin molecule, and fusions of immunologically active portions of an immunoglobulin molecule. The antibodies described herein are capable of specifically complexing with, binding to, identifying or detecting an epitope of an antigen, e.g., SARS-CoV-2 spike variants with N501 but not N501Y. Unless otherwise indicated, the term “antibody” includes, in addition to antibodies comprising two full-length heavy chains (each chain comprising a variable region and a constant region) and two full-length light chains (each chain comprising a variable region and a constant region), modifications, antigen or epitope binding fragments, as well as “antibody mimics” or “antibody equivalents” or muteins thereof. In one embodiment, an “antibody” refers to an intact immunoglobulin, such as an IgA, IgD, IgE, IgG, and IgM, or to an antigen binding portion thereof that competes with the intact antibody for specific binding, unless otherwise specified. In one embodiment, an intact antibody is an IgG1, IgG2, IgG3 or IgG4. Heavy and light chain variable domain sequences and CDRs may be selected from those described herein, including in those provided in FIG.8A and FIG.8B and the in the Sequence Listing, e.g., SEQ ID NOs: 1-26. As used herein, an “antibody” or “antigen/epitope binding fragment” as described herein refers to an anti-SARS-CoV-2 spike protein antibody designated 2E8 or fragment thereof based upon the sequences defined herein. Such an antibody or fragment includes a monoclonal antibody, a synthetic antibody, a recombinant antibody, a chimeric antibody, a humanized antibody, a human antibody, a CDR-grafted antibody, a multi-specific binding construct that can bind two or more epitopes, a dual specific antibody, a bi-specific antibody, a multi-specific antibody, an affinity matured antibody, a single antibody chain or an scFv fragment, a diabody, a single chain comprising complementary scFvs (tandem scFvs) or bispecific tandem scFvs, an Fv construct, a disulfide-linked Fv, a Fab construct, a Fab' construct, a F(ab')2 construct, an Fc construct, a monovalent or bivalent construct from which domains non-essential to monoclonal antibody function have been removed, a single-chain molecule containing one VL (variable region of light chain), one VH (variable region of heavy chain) antigen-binding domain, and one or two constant “effector” domains optionally connected by linker domains, a univalent antibody lacking a hinge region, a single domain
antibody, a dual variable domain immunoglobulin (DVD-Ig) binding protein or a nanobody, or any recombinant versions thereof. Definitions and examples of these types of structures are found in the art and in, e.g., US Patent No.9,902,772, incorporated by reference herein. “Recombinant antibody” refers to an antibody that is expressed from a cell or cell line transfected with one or more expression vectors comprising a coding sequence of the antibody, where said coding sequence is not naturally associated with the cell or naturally occurred in the cell. Said cell may be termed as a host cell. In certain embodiments, the host cell may be a non-human cell or non-human cell line. In certain embodiments, the host cell may be a non-mammalian cell or cell line, for example, an insect cell or cell line, a yeast cell or cell line, or an E coli cell or cell line. In certain embodiments, the host cell may be a mammalian cell or cell line. In certain embodiments, the host cell may be a non-human mammalian cell or cell line. In certain embodiments, the host cell may be a human cell or cell line, for example a human embryonic kidney 293 cells or a hybridoma cell or cell line. In one embodiment, a recombinant antibody has a glycosylation pattern that is different than the glycosylation pattern of an antibody having the same sequence if it were to exist in nature. In one embodiment, a recombinant antibody is expressed in a mammalian host cell which is not a human host cell. Notably, individual mammalian host cells have unique glycosylation patterns. In certain embodiments, the antibody is produced using the on-cell mAb screening system described by Puligedda et al, MAbs, 2019 Apr;11(3):546-558. doi: 10.1080/19420862.2019.1574520. Epub 2019 Feb 22, which is incorporated herein by reference. Methods for producing such antibodies are well-known in the art. Indeed, commercial vectors for certain antibody and antibody fragment constructs are available. The antibody may also be a protein (e.g., a fusion protein) comprising at least one antibody or antibody fragment. In an embodiment, the antibody comprises an Fc region. In particular embodiments, these anti- antibodies and fragments thereof have a binding affinity (Ka) for an epitope of at least 103M. In other embodiments, the antigen binding proteins exhibit a Ka of at least 103 M, at least 104 M, at least 105 M, or at least 106 M. As used herein, an “antibody mimic” or an “antibody equivalent” refers to a molecule (for example, an amino acid sequence, a protein, or a modified or conjugated version thereof). For example, affibodies, i.e., a class of engineered affinity proteins, generally small (~6.5 kDa) single domain proteins that can be isolated for high affinity and specificity to any given target, aptamers, polypeptide molecules that bind to a specific target, an affilin, an affitin, an affimer, an alphabody, an anticalin, an avimer, a DARPin (designed ankyrin repeat
proteins), a Fynomer, a Kunitz domain peptide, a monobody, a peptabody and others known in the art. As used herein, a “modification” of an amino acid sequence (e.g., antibody or a fragment thereof) comprises an amino acid sequence wherein one or more amino acid residues are inserted into, deleted from, or substituted into the reference amino acid sequence, e.g., any of amino acid sequence encoding the variable light or heavy chains, and/or CDRs of antibody 2E8. One such modification is the replacement of one amino acid in such a sequence, e.g., any of SEQ ID NO: 1 to 26, with a conservative amino acid. Other modifications include, for example, fusion proteins formed by fusing the heavy chain of a selected antibody into an Ig backbone. Still another modification includes an antibody that has been modified via conjugation to another chemical moiety (such as, for example, polyethylene glycol or albumin, e.g., human serum albumin), or a post-translational modification, such as phosphorylation, glycosylation, acylation, acetylation, formylation, alkylation, amidation, arginylation, polyglutamylation, polyglycylation, butyrylation, gamma- carboxylation, polysialylation, malonylation, hydroxylation, iodination, nucleotide addition, phosphate ester or phosphoramidate, propionylation, pyroglutamate formation, S- glutathionylation, S-nitrosylation, S-sulfinylation, S-sulfonylation, succinylation addition of a succinyl group to lysine, and sulfation. In another embodiment, a modification of antibody 2E8 is a single chain human antibody, having a variable domain region from a heavy chain and a variable domain region from a light chain and a peptide linker connecting the heavy chain and light chain variable domain regions. As used herein, an antibody construct (e.g., an antibody, an antibody heavy chain, an antibody light chain, or any fragment or modification thereof) comprises three Complementarity-Determining Regions (CDRs, also known as HV, hypervariable regions, namely CDR1, CDR2, CDR3, from N-terminal to C-terminal, or 5’ to 3’ when corresponding nucleic acid sequence is referenced), and four framework regions (FRs, namely FR1, FR2, FR3 and FR4, from N-terminal to C-terminal, or 5’ to 3’ when corresponding nucleic acid sequence is referenced). See, e.g., Janeway, Charles A Jr; Travers, Paul; Walport, Mark; Shlomchik, Mark J (2001). Immunobiology: The Immune System in Health and Disease (5 ed.). New York: Garland Science. ISBN 0-8153-3642-X, which is incorporated herein by its entirety. It would be understood that in the antibody construct, CDRs are arranged non- consecutively, not immediately adjacent to each other, and may be separated by an FR. As part of the variable chain in an antibody construct and T cell receptors generated by B-cells and T-cells respectively, CDRs are where an antigen specifically binds.
In certain embodiments, the antibody has one or more of the CDRs set forth in the table below. In some embodiments, the antibody has 1, 2, or all three of the CDRs from the heavy chain. In some embodiments, the antibody has 1, 2, or all three of the CDRs from the light chain. In some embodiments, the antibody has all 6 CDRs as described below. Table 1: 2E8 Antibody Variable Chain CDRs
It would be understood by one of skill in the art that the antibody constructs, fragments or modifications, and CDR described herein may be used in any embodiment, composition, reagent, or method, including those also described herein. It would also be understood that an antibody, antibody construct, fragment or modification provided herein may comprise an FR or a non-CDR J-region, other than those identified provided in the incorporated Sequence Listing. Such an antibody, antibody construct, fragment or modification may have a binding affinity and/or specificity to its SARS-CoV2 spike protein epitope or antigen at about 20%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 97%, about 99%, about 100%, more than about 100%, about 200%, about 300%, or about 500% of that of any antibody constructs described in this specification. Conventional methods, including enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), MSD assay, and antibody phage display library, may be used to determine such binding affinity and/or specificity. As used herein, the term “immunologically specific” refers to proteins or polypeptides, particularly antibodies, that bind to one or more epitopes of a protein or compound of interest, but which do not substantially recognize and bind other molecules in a sample containing a mixed population of antigenic biological molecules.
An “epitope” as used herein refers to the portion of a SARS-CoV2 spike protein or any naturally occurring or synthetic or recombinant amino acid sequence that is capable of specifically complexing with one or more of the antibodies or fragments or modified antibodies, as described herein. An epitope can comprise non-contiguous portions of the molecule (e.g., in a polypeptide, amino acid residues that are not contiguous in the polypeptide's primary sequence but that, in the context of the polypeptide's tertiary and quaternary structure, are near enough to each other to be bound by an antigen binding protein). In one embodiment, the epitope to which an anti-SARS-CoV2 spike protein antibody as described herein binds includes the residue N501 but not N501Y. See, Liu, H., Zhang, Q., Wei, P. et al. The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. Cell Res 31, 720–722 (April 2021), which is incorporated herein by reference. The terms “percent (%) identity”, “sequence identity”, “percent sequence identity”, or “percent identical” in the context of amino acid sequences or nucleotide sequences refers to the residues in the two sequences which are the same when aligned for correspondence. Percent identity may be readily determined for amino acid sequences or nucleotide sequences over the full-length of a protein, polypeptide, or encoding region thereof, e.g., about 15 amino acids, about 150 amino acids, or a peptide fragment thereof or the corresponding nucleic acid sequence coding sequences. A suitable amino acid fragment may be at least about 4 amino acids in length and may be up to about 200 or up to about 700 amino acids or nucleotide fragments of from about 12 nucleotides to about 600 to 2100 nucleotides. Generally, when referring to “identity”, “homology”, or “similarity” between two different sequences, “identity”, “homology” or “similarity” is determined in reference to “aligned” sequences. “Aligned” sequences or “alignments” refer to multiple nucleic acid sequences or protein (amino acids) sequences, often containing corrections for missing or additional bases or amino acids as compared to a reference sequence. Alignments are performed using any of a variety of publicly or commercially available Multiple Sequence Alignment Programs. Sequence alignment programs are available for amino acid sequences, e.g., the “Clustal Omega”, “Clustal X”, “MAP”, “PIMA”, “MSA”, “BLOCKMAKER”, “MEME”, and “Match-Box” programs. Generally, any of these programs are used at default settings, although one of skill in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program which provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. See, e.g., (THOMPSON et al.1999).
As used herein, the “conservative amino acid replacement” or “conservative amino acid substitutions” refers to a change, replacement or substitution of an amino acid to a different amino acid with similar biochemical properties (e.g., charge, hydrophobicity and size), which is known by practitioners of the art. Also see, e.g., FRENCH et al.1983, and YAMPOLSKY et al.2005. In certain embodiments, a CDR of the disclosed antibody or fragment thereof is free of conservative amino acid replacement. “Patient” or “subject” or “host” as used herein means a male or female mammalian animal, including a human, a veterinary or farm animal, a domestic animal or pet, and animals normally used for clinical research. In one embodiment, the subject of these methods and compositions is a human. The term “prevent” refers to the prophylactic treatment of a subject who is at risk of developing a condition resulting in a decrease in the probability that the subject will develop the condition. The term “treat” as used herein refers to any type of treatment that imparts a benefit to a patient afflicted with a disease, including improvement in the condition of the patient (e.g., in one or more symptoms), delay in the progression of the condition, or reduction in severity of the disease and its symptoms. As used herein, “disease”, “disorder” and “condition” are used interchangeably, to indicate an abnormal state in a subject. A “therapeutically effective amount” of a compound or a pharmaceutical composition refers to an amount effective to prevent, inhibit, treat, or lessen the symptoms of a particular disorder or disease. “Pharmaceutically acceptable” indicates approval by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. A “carrier” refers to, for example, a diluent, adjuvant, excipient, auxiliary agent or vehicle with which an active agent of the present invention is administered. Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described, for example, in “Remington's Pharmaceutical Sciences” by E.W. Martin. Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as
peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. In general, the pharmaceutically acceptable carrier of the composition is selected from the group of diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. The compositions can include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; and additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80), antioxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol). The compositions can also be incorporated into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc., or into liposomes or nanoparticles. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of components of the pharmaceutical composition described herein. As used herein, a “reaction zone” is defined as a region on the solid support of a diagnostic device containing predetermined concentrations of capture antibodies, attached to the solid support, each capture antibody capable of recognizing and binding a distinct epitope of a test protein or antigen (i.e., SARS-CoV-2 spike protein). As discussed herein, the reaction zone can be any designated region or portion of a membrane strip, or it can be in a container such as a test tube, or it can consist of a well in a microtiter plate. The reaction zone provides a specific location for detecting the presence and range of concentration of an antigen in a biological sample. As used herein, a “reagent zone” is defined as a region of a diagnostic device as described herein containing a mixture of incubation antibodies that are identical in type to the capture antibodies in the reaction zone, and a detection antibody. The reagent zone is preferably provided on the device as a designated region or portion of a membrane strip. Alternatively, the reagent zone is separate from the solid support containing the reaction zones for example, in a container such as a test tube or as a well in a microtiter plate. A test protein or antigen (i.e., SARS-CoV-2 spike protein in a sample is exposed to the reagent zone prior to being exposed to any reaction zone. The reagent zone is typically formed using an incubation solution containing incubation antibodies and other reagents, such as inert proteins and non-ionic detergent, to solubilize the test antigen and antibodies, and to reduce non- specific binding of the test antigen and antibodies. As used herein, a “capture antibody” is defined as an antibody, attached to the solid support of the device of the invention in a reaction zone. Each capture antibody is selected to
recognize and bind a particular, distinct epitope of the test protein or antigen (i.e., SARS- CoV-2 spike protein at a predetermined concentration, and is identical in type to an incubation antibody in the reagent zone. As used herein, a “detection antibody” is defined as an antibody, that recognizes and binds the test protein or antigen (i.e., SARS-CoV-2 spike protein) at a binding site or epitope distinct from that of the incubation and capture antibodies. The detection antibody is coupled to a detectable label such as a chromophore, enzyme, radioisotope, or colored particle, such as colloidal gold or color latex. Examples of enzymes include, but are not limited to, alkaline phosphatase, beta galactosidase, or horseradish peroxidase which produce color when incubated with the appropriate substrate. The concentration of detection antibody to use in the device of the invention is predetermined by conducting experiments to determine amounts of detection antibodies that are needed to provide a detectable signal. It should be understood that while various embodiments in the specification are presented using “comprising” language, under various circumstances, a related embodiment is also described using “consisting of” or “consisting essentially of” language. “Comprising” is a term meaning inclusive of other components or method steps. When “comprising” is used, it is to be understood that related embodiments include descriptions using the “consisting of” terminology, which excludes other components or method steps, and “consisting essentially of” terminology, which excludes any components or method steps that substantially change the nature of the embodiment or invention. With regard to the description of these inventions, it is intended that each of the compositions herein described, is useful, in another embodiment, in the methods of the invention. In addition, it is also intended that each of the compositions herein described as useful in the methods, is, in another embodiment, itself an embodiment of the invention. It is to be noted that the term “a” or “an”, refers to one or more, for example, “an antibody”, is understood to represent one or more antibody/antibodies. As such, the terms “a” (or “an”), “one or more,” and “at least one” is used interchangeably herein. As used herein, the term “about” means a variability of plus or minus 10 % from the reference given, unless otherwise specified. Unless defined otherwise in this specification, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs and by reference to published texts, which provide one skilled in the art with a general guide to many of the terms used in the present application.
Antibody 2E8 Provided herein is a monoclonal antibody, designated 2E8, that distinguishes between SARS-CoV-2 spike variants with N501 and N501Y. As this is one of the most important mutations found in SARS-CoV-2 spike proteins expressed by medically important variants, this mAb has utility for diagnosis of present and future SARS-CoV-2 strains. The antibody described (2E8) has anti-viral activity and is useful in the treatment of disease caused by N501 containing SARS-CoV-2. As used herein the term “2E8 antibody” may refer to the monoclonal antibody described herein derived from the hybridoma or antibodies that contain fragments derived from that sequence. As a non-limiting example, an ScFv having the variable heavy chain of the 2E8 monoclonal antibody and the variable light chain of the 2E8 monoclonal antibody may be referred to herein as the 2E8 antibody. Recombinant, synthetic, monoclonal or other antibodies or fragments that bind to one or more SARS-CoV2 spike protein epitopes that include the residue N501 include, in one embodiment a heavy chain variable domain SEQ ID NO: 14 and/or light chain variable domain sequence SEQ ID NO: 21 (antibody 2E8), or sequences at least 80% (for example, about 85%, about 86%, about 87% about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100%) identical thereto. In certain embodiments, antibodies or fragments that bind to one or more SARS-CoV2 spike protein epitopes that include the residue N501 include any one or two or all three CDRs of the heavy chain of antibody 2E8. In certain embodiments, antibodies or fragments that bind to one or more epitopes that include the residue N501 include any one or two or all three CDRs of the light chain of antibody 2E8. In certain embodiments, antibodies or fragments that bind to one or more epitopes that include the residue N501 include any one or two or three or four or five or all six CDRs of antibody 2E8. In certain embodiments, the nucleic acid sequence is suitable for expression of the antibodies or fragments thereof in a host cell. Fragments of antibody 2E8 heavy chain nucleotide sequence SEQ ID NO: 1 and amino acid sequence SEQ ID NO: 14 include those sequences identified in the table below. Table 2: Heavy Chain Variable Sequence of mAb 2E8
Fragments of antibody 2E8 light chain nucleotide sequence SEQ ID NO: 8 and amino acid sequence SEQ ID NO: 21 include those sequences identified in the table below. Table 3: Light Chain Variable Sequence of mAb 2E8
The antibodies and antibody constructs may be further modified from those exemplified. In a particular embodiment, the domains of the antibody or antibody fragment have at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% homology or identity with the domains present in the anti- monoclonal antibody 2E8, and illustrated in the sequences identified in herein, in the Sequence Listing, and the tables above. The domains in the tables may be longer or shorter than the domains identified in the tables by about 1, 2, 3, 4, or 5, amino acids, particularly 1 or 2 amino acids, at the N terminus and/or C-terminus of the domain. The domains may be encoded by nucleotide sequences longer or shorter than those in the Sequence listings by 3, 6, 9, 12, or 15 nucleotides, particularly 3 or 6 nucleotides, at the 5’ terminus and/or 3’ terminus of the sequence encoding a domain. In certain embodiments, the CDR of an antibody can be determined by one of skill in the art, for example, via various databases, software, or algorithms. See, www.imgt.org. In
certain embodiments, the CDRs are illustrated in FIG.8A and FIG.8B as well as provided in Table 2 and Table 3. In certain embodiments, the CDRs comprises one or two or three or four or five or six more or less amino acids at the N-terminal side and/or C-terminal side of the CDRs as illustrated herein. In certain embodiments, the CDRs are shifted toward the N- terminal side or the C-terminal side by one or two or three or four or five or six or seven or eight or nine or ten amino acid(s) compared to the ones as illustrated in FIG.8A and FIG.8B and provided in Table 2 and Table 3. In one embodiment of a modification, the antibodies may be converted into a non- human immunoglobulin format. In a particular embodiment, the selected sequences of the heavy or light chains of any of the antibodies disclosed herein (or a portion thereof) are inserted into the backbone of a non-human antibody or antibody fragment construct. For example, the variable light domain and/or variable heavy domain of the antibodies described herein may be inserted into another antibody construct. Still another embodiment comprises a fully human Fab antibody fragment having a heavy chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 14; or having a light chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 21 or combinations thereof. Still other modifications of the antibodies are single chain antibodies having a heavy chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 14, and a light chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 21, and combinations thereof, with a peptide linker connecting the heavy and light chains. These same combinations can be generated by use of the corresponding chain encoding nucleotide sequences or sequences having at least 80, 85, 90, 95 or 99% identity thereto. The production of antibodies or fragments that specifically bind to a SARS-CoV2 spike protein epitope that include the residue N501, can utilize any of the amino acid sequences of the heavy chain and light chain variable regions, or the nucleotide sequences encoding same, i.e., SEQ ID NOs: 1 to 21, or the other fragments of the antibodies identified herein, including epitope binding fragments, or modifications thereof as described. In one embodiment, polyclonal antibody compositions are typically produced by immunizing a selected mammal, e.g., a primate, rodent, or human, with a peptide/ polypeptide composition containing a specific epitope. The selection of high titer, high affinity polyclonal antibodies can be monitored by standard techniques, such as with an enzyme-linked immunosorbent assay and surface plasma resonance. If desired, the polyclonal antibody molecules can be
isolated from the mammal, e.g., from the whole blood, plasma or serum, and further purified from the plasma or serum of the immunized mammal by conventional techniques. Conventional harvesting techniques can include plasmapheresis, protein A and G chromatography, among others. Such polyclonal antibody compositions may themselves be employed as pharmaceutical compositions as described herein. In another embodiment, monoclonal antibodies are made by now conventional techniques, using antibody producing cells obtained from the immunized mammals and fused to non-IgG-producing myeloma cells to form hybridomas or from selection from activated immune B cells with extraction by known molecular biological techniques. These monoclonal antibodies can be further used to prepare other forms of antibodies, e.g., chimeric antibodies, humanized antibodies, human antibodies. Other antibody fragments or ligands can be produced by screening phage display libraries, antibody fragments and mixtures thereof. Techniques for generating these types of antibodies and ligands are well-known in the art and the ligands themselves may be generated using the disclosed amino acid sequences of the above-identified epitopes. Chimeric antibodies may similarly be developed using known techniques. Chimeric antibodies are molecules in which different portions are derived from different animal species. Single chain antibodies may also be prepared by conventional methods, such as described in US Patent Nos.4,946,778 and 4,704,692 using the variable portions of the polyclonal or monoclonal antibodies produced according to this invention. The production of bi-specific antibodies or ligands that specifically bind to two or more selected epitopes, can employ conventional techniques. See, e.g., Hornig N, Färber- Schwarz A., “Production of bispecific antibodies: diabodies and tandem scFv.”, 2012, Methods Mol Biol., 907:713-27; Speiss, C. et al, Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies, Jul 7, 2013, Nature Biotechnology, 31:753-758; and Jonathan S Martin and Zhenping Zhu, “Recombinant approaches to IgG-like bispecific antibodies”, 2005 Acta Pharmacologica Sinica, 26: 649– 658. The availability of nucleic acid molecules encoding the heavy and light chains of a SARS-CoV2 spike protein antibody also enables production of a recombinant antibody, fragment or modification using in vitro expression methods and cell-free expression systems known in the art. In vitro transcription and translation systems are commercially available, e.g., from Promega Biotech (Madison, WI) or Gibco-BRL (Gaithersburg, MD). The antibodies, epitope-binding fragments or modifications thereof may also be produced by
expression in a suitable prokaryotic or eukaryotic system. Similarly modifications may be inserted by use of a variety of CRISPR techniques and other related, e.g., zinc finger, methodologies for modifying amino acid and nucleotide sequences. Antibody recombinant engineering techniques are well-taught in the art including in publications, texts and reviews, such as Edwards, W. B., Xu, B., Akers, W., Cheney, P. P., Liang, K., Rogers, B. E., et al. (2008). Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjug. Chem.19, 192–200; Roque, A. C., Lowe, C. R., and Taipa, M. A. (2004). Antibodies and genetically engineered related molecules: production and purification. Biotechnol. Prog.20, 639–654; Smith, G. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317; Saeed, AFUH et al, Antibody Engineering for Pursuing a Healthier Future, Front. Microbiol., 28 March 2017; 8:495; Green, MR and Sambrook, J., 2012, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, all incorporated herein by reference. The antibodies of the instant invention may also be conjugated/linked to other components. For example, the antibodies may be operably linked (e.g., covalently linked, optionally, through a linker) to at least one detectable agent, imaging agent, contrast agent, or therapeutic compound (e.g., see above). The antibodies of the instant invention may also comprise at least one purification tag (e.g., a His-tag). The antibody molecules of the invention may be prepared using a variety of methods known in the art. Polyclonal and monoclonal antibodies may be prepared as described in Current Protocols in Molecular Biology, Ausubel et al. eds. Antibodies may be prepared by chemical cross-linking, hybrid hybridoma techniques and by expression of recombinant antibody fragments expressed in host cells, such as bacteria or yeast cells. In one embodiment of the invention, the antibody molecules are produced by expression of recombinant antibody or antibody fragments in host cells. The nucleic acid molecules encoding the antibody may be inserted into expression vectors and introduced into host cells. The resulting antibody molecules are then isolated and purified from the expression system. The antibodies optionally comprise a purification tag by which the antibody can be purified. The purity of the antibody molecules of the invention may be assessed using standard methods known to those of skill in the art, including, but not limited to, ELISA, immunohistochemistry, ion-exchange chromatography, affinity chromatography, immobilized metal affinity chromatography (IMAC), size exclusion chromatography, polyacrylamide gel electrophoresis (PAGE), western blotting, surface plasmon resonance and mass spectroscopy.
Still other antibody modifications employing the SEQ ID Nos disclosed herein, e.g., as taught by the techniques referenced in above-cited US Patent Publication No. US2019/0062452, incorporated by reference herein. Diagnostic Methods In another aspect, the anti-SARS-CoV-2 antibodies described herein are useful in diagnosing COVID-19 infection. Herein is described 2E8, a human antibody that binds the Wuhan-Hu-1 spike having N501 with high affinity, but does not bind variants containing the N501Y mutation. This mutation is shared among the Variants Being Monitored (VBMs) alpha, B.1.1.7, beta, B.1.351, gamma, P.1., and mu B.1.621. Given the global predominance of delta (B.1.167), which is bound by the 2E8, identifying of a SARS-CoV-2 strain that does not bind 2E8 will reveal an infection with a non-delta strain. The use of the 2E8 in an antigen diagnostic test (ADT) has immediate utility for monitoring the ingress of SARS-CoV-2 variants that do not contain this mutation. The residue recognized by the 2E8 antibody, N501, lies on the “right shoulder” of the RBD and is involved in hydrophobic interactions with ACE2 during receptor binding [Vazquez-Lombardi R., et al. Nat. Protoc.2018;13:99–117; Tursi S.A., et al., et al. Nat. Commun.2020;11:1007]. The N501Y mutation does not appear to globally alter the structure of the spike, rather, it allows tyrosine side-chain interactions that enhance ACE2 binding affinity that likely mediate the increased infectivity of N501Y-containing viruses [Vazquez- Lombardi R., et al. Nat. Protoc.2018;13:99–117; Tursi S.A., et al., et al. Nat. Commun.2020;11:1007]. Without wishing to be bound by theory, this may explain why the 2E8 is sensitive to a single residue change and not affected by the other RBD mutations. The 2E8 binds the same epitope on the spike, but with interactions that make it useful for variant detection. The 2E8 binding site overlaps the CB6 site, yet its binding is not affected by changes at K417, and CB6 binding is largely insensitive to the N501Y change [Zahradnik J., et al. Nat. Microbiol.2021;6:1188–1198]. This highlights the structural independence of these two epitopes in the variant RBDs. In one embodiment, a method of detecting, or screening for, a SARS-CoV-2 infection in a subject. The method includes contacting a sample from the subject with a 2E8 antibody, as described herein, wherein, in the presence of a SARS-CoV-2 spike protein having the N501 residue, binds the same, and detecting the bound complex. As used herein, the term “sample” includes any product produced by a subject, or a product derived therefrom. A sample may be taken from any tissue or bodily fluid, e.g., a blood sample (including blood-
derived samples), serum sample, lymph sample, saliva sample, synovial fluid sample, phlegm, nasal swab, etc. A blood-derived sample may be a selected fraction of a patient's blood, e.g., a selected cell-containing fraction, or a plasma or serum fraction. In certain embodiments, the sample is a nasal swab. In certain embodiments, the antibodies are useful in an assay, such as an immunoassay, for detecting or typing a SARS-CoV-2 infection in a subject. In one embodiment, the immunoassay is an ELISA, or “sandwich assay”. Methods of performing sandwich assays are known in the art. For example, one antibody is coupled to a solid support, and a second antibody is coupled to a detectable label. A test antigen having separate binding sites (epitopes) for the first and second antibodies is exposed to the antibody coupled to the solid support such that the antigen binds to that antibody. Subsequently, the labeled second antibody is added to the support to permit the binding of the labeled second antibody to the test antigen. Thus, the amount of the antigen present in a sample is a function of the amount of detected label bound to the second antibody bound to the antigen. Examples of such detectable labels include chromophores, radioisotopes, or enzymes which can be converted into a product that can be measured photometrically. The 2E8 antibodies may be used alone, or in conjunction with other antibodies, in sandwich and other types of assays, to provide a specific diagnosis of the SARS-CoV-2 variant in a clinical sample. For example, referring to Table 5 below, the 2E8 antibody binds the SARS-CoV-2 delta strain, but not alpha, beta, or gamma. The 2E8 antibody may be used in conjunction with a second antibody that can be used as a positive control for the presence of SARS-CoV-2, in which the second antibody binds SARS-CoV-2 spike protein regardless of the amino acid at position 501. An example here is the anti 6XHIS tag antibody, which binds a polypeptide tag appended to the N terminus of the recombinant spike proteins tested. In a clinical test for detection of SARS-CoV-2 virions (which do not express a 6XHIS tag) any of a number of pan-SARS-CoV-2 specific antibodies could be used that are known to be state of the art. For additional differentiation among SARS-CoV-2 variants, VOCs, VBMs, etc. an additional mAb could be used. An example shown in the instant invention is CB6, which binds alpha and gamma strains, but not beta, and therefore differentiates among the N501Y mutated strains by providing specific binding to B.1.1.7 and P.1, but no binding to B.1.351. Many other mAbs known to the state of the art could be combined in a 2E8-based testing strategy to create rapid antigen diagnostic tests for diagnosis of SARS-CoV-2 variants in point-of-care testing and epidemiological surveillance.
Various ADTs have been granted Emergency Use Authorization in the US. These include those in Table 4 below. The 2E8 antibody is useful with the ADTs shown in the table. Table 4: ADTs granted Emergency Use Authorization
In one embodiment, the antibody is useful in an ADT. The ADT, in certain embodiments, includes a diagnostic device that includes a solid support, such as a membrane strip, having a plurality of sequentially arranged reaction zones, and preferably, at least one reagent zone (FIG.9A, FIG.9B, well A). The membrane strip may be made of synthetic or natural materials, such as polystyrene, nylon, nitrocellulose membrane, or filter paper. The reaction zones contain capture antibodies that bind epitopes of a SARS-CoV-2 spike protein. In one embodiment, the strip contains one reaction zone, that contains the 2E8 antibody as the capture antibody. In another embodiment, the strip contains at least one additional reaction zone, wherein one of the additional reaction zones includes a capture antibody that binds alpha and gamma strains, but not beta or delta. In another embodiment, the strip contains at least one additional reaction zone, wherein one of the additional reaction zones includes a capture antibody that presumptively binds all strains of SARS-CoV-2. The solid support permits a solution containing the sample being assayed to be transferred to each of the reaction zones by diffusion, or by physical means, such as pipetting (FIG.9A and FIG.9B). Other suitable solid supports include, but are not limited to, microtiter plates, chromatographic membranes, or other immunoassay devices such as silica chips (Affmatrix, Palo Alto, Calif.). In certain embodiments, such as those shown in FIG.9A and FIG.9B, the 2E8 capture antibody is attached at the first reaction zone (well B), the C6B capture antibody is attached at the second reaction zone (well C), and a capture antibody that presumptively binds all COVID-19 strains is attached at the third reaction zone. The capture antibodies are attached to the membrane strip, for example, by physical attachment as a result of the “stickiness” of the antibodies, or by chemical reaction coupling, so that they will not become soluble and detach when the membrane strip becomes wet. In other words, the capture antibodies can be understood to generally form a solid phase in the reaction zones. In
some embodiments, the solid support is provided without a reagent zone, and the sample is administered directly into the first reaction zone, and optionally additional reaction zones. In some embodiments, the ADT includes a detection antibody. The detection antibody may be an antibody that binds to a different antigen on the SARS-CoV-2 spike protein. In other embodiments, the 2E8 antibody is biotinylated, and the antibody-antigen binding is detected with, e.g., a streptavidin-HRP conjugate. The reactions are then developed with OPD substrate. Other enzyme substrates are known in the art and useful herein and include, without limitation, TMB (3,3',5,5'-tetramethylbenzidine), ABTS (2,2'-Azinobis [3- ethylbenzothiazoline-6-sulfonic acid]-diammonium salt, OPD (o-phenylenediamine dihydrochloride), PNPP (p-Nitrophenyl Phosphate), ONPG (o-nitrophenyl-β-D- galactopyranoside). Useful enzymes include, without limitation, horseradish peroxidase and alkaline phosphatase. The incubation solution used to form the reagent zone also contains inert proteins, such as bovine serum albumin (BSA); and a non-ionic detergent, such as Tween-20®. In addition, the incubation solution can include other components, such as casein, gelatin, nonfat dry milk, ovalbumin, polyvinyl pyrrolidone, polyvinyl alcohol, or animal serum components including bovine IgG, murine IgG, and goat IgG, to improve the usability and performance of the device of the invention. The particular components, in addition to the incubation and detection antibodies, used in the incubation solution and their concentrations vary depending on the antigen being tested and the experimental conditions of the assay. The components are preferably chosen based on results of empirical test experiments. The components are selected to optimize the results obtained with the device of the invention, for example, components are preferably chosen to increase the intensity and contrast of antigen specific staining, and minimize background staining, thereby optimizing the signal to noise ratio of the device of the invention. The incubation solution is prepared by mixing the foregoing components in a buffer solution, such as phosphate buffered saline (PBS). In certain embodiments, the reagent zone is generated by placing a volume (e.g., 10 μl) of the incubation solution onto the membrane strip near one end, and allowing the incubation solution to dry for transport and/or storage before use. Due to the presence of reagents, such as the inert proteins and Tween-20, the incubation and detection antibodies become soluble to facilitate diffusion of the antibody/antigen complexes to the sequentially arranged reaction zones as the membrane becomes wet during the course of the assay.
Pharmaceutical Compositions Compositions comprising at least one anti-SARS CoV-22E8 antibody are also described herein. In a particular embodiment, the composition comprises at least one anti- SARS CoV-22E8 antibody or antibody fragment that binds a spike protein epitope having the residue N501, as described herein, and at least one pharmaceutically acceptable carrier. The composition may further comprise at least one other therapeutic compound for the inhibition, treatment, and/or prevention of COVID-19. Alternatively, at least one other therapeutic compound may be contained within a separate composition(s) with at least one pharmaceutically acceptable carrier. The present invention also encompasses kits comprising a first composition comprising at least one anti-SARS CoV-2 antibody or antibody fragment and a second composition comprising at least one other therapeutic compound for the inhibition, treatment, and/or prevention of COVID-19, as known in the art, and further described herein. The first and second compositions may further comprise at least one pharmaceutically acceptable carrier. As explained hereinabove, the compositions of the instant invention are useful for treating autoantibody related diseases or disorders. A therapeutically effective amount of the composition may be administered to the subject. The dosages, methods, and times of administration are readily determinable by persons skilled in the art, given the teachings provided herein. In yet another aspect, a pharmaceutical composition for the treatment of COVID-19 comprises at least one antibody or epitope-binding fragment as described above and a pharmaceutically acceptable carrier. In one embodiment, the composition contains one or more antibodies, as described above. In another embodiment, the composition contains a fragment or other of the above-noted modifications of one or more of these antibodies. In still another embodiment, the pharmaceutical composition comprises one of more of a heavy chain variable domain sequence of SEQ ID NOs: 14, or a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identity to one of the sequences; or having a light chain variable domain sequence at least 80, 85, 90, 95 or 99% identity to an amino acid sequence of SEQ ID NO: 21, or combinations thereof. Other pharmaceutical compositions can be generated by use of the corresponding chain encoding nucleotide sequences SEQ ID NOs: 8 and 1, or sequences having at least 80, 85, 90, 95 or 99% identity thereto, e.g., for delivery in vectors, viruses and the like. Still another pharmaceutical compositions contain a mixture of two or more of the antibodies or epitope binding antibody fragments as described above and a pharmaceutically acceptable carrier.
In these compositions, the antibodies, fragments or modifications are present in an amount effective to bind a SARS-CoV-2 variant having an N501 residue and neutralize or inhibit the effect of the virus. In another embodiment, the composition contains a fragment or other of the above- noted modifications of one or more of these antibodies. In still another embodiment, the pharmaceutical composition comprises one of more of a heavy chain variable domain sequence identified herein, one of more of a light chain variable domain sequence identified herein, or a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to one of these sequences, or a fragment or modification thereof. Suitable pharmaceutical carriers or excipients for such compositions include, without limitation, the diluent, adjuvant, excipient, auxiliary agent, carrier or vehicle with which an antibody, fragment or modification thereof is administered, as described above. Methods of Treatment The compositions comprising these anti-SARS-CoV-2 spike variant with N501 antibodies may be used in methods for the inhibition, prevention, and/or treatment of COVID-19. The methods comprise administering at least one anti-SARS-CoV-2 antibody to a subject. The methods of the instant invention may further comprise the administration of at least one other therapeutic for COVID-19. For example, the anti-SARS-CoV-2 antibodies may be co-administered with an anti-inflammatory agent and/or immunosuppressant. The agents administered to the subject may be contained within a composition comprising at least one pharmaceutically acceptable carrier. When more than one agent is being administered (e.g., anti-SARS-CoV-2 antibody with an additional therapeutic), the agents may be administered consecutively (before or after) and/or at the same time (concurrently). The agents may be administered in the same composition or in separate compositions. As stated hereinabove, the methods (and compositions) described herein comprise administering at least one antibody or antibody fragment which is immunologically specific for SARS-CoV-2 spike protein with N501 (anti-SARS-CoV-2 antibody) to a subject. In a particular embodiment, the anti-SARS-CoV-2 antibody is immunologically specific for SARS-CoV-2 spike protein with N501 to the exclusion of SARS-CoV-2 spike protein with N501Y. The antibodies, fragments and modifications of the anti-SARS-CoV-2 antibody described herein are useful in methods for treating COVID-19, that comprises administering
an effective amount of a single antibody or epitope binding fragment or a mixture of antibodies or fragments. In another aspect, a method for treating a subject suspected of having COVID-19, comprises administering an effective amount of a single antibody or epitope binding fragment or a mixture of antibodies or fragments as described herein. In another aspect, a method for treating a subject with such a disease comprises administering an effective amount of a single antibody or epitope binding fragment or a mixture of antibodies or fragments as described herein. In one embodiment, the antibody comprises antibody 2E8 or fragments or modifications thereof. In another embodiment, the antibody comprises any of the heavy chain sequences of SEQ ID NOs: 14, an epitope binding fragment or a modification thereof. In another embodiment, the antibody comprises any of the light chain sequences of SEQ ID NOs: 21, an epitope binding fragment or a modification thereof. In one embodiment, the antibody and antibody fragment may comprise at least one domain from the 2E8 monoclonal antibody described herein. See FIG.8A and FIG.8B and Table 1 for the sequences of the heavy, chain, light chains, CDRs, framework regions, and encoding nucleic acid sequence of these above referenced antibodies. These exemplified sequences can be used to generate the same antibodies or modifications or fragments thereof. For example, the antibody or antibody fragment may comprise at least one, two, three, four, five, or all six complementarity-determining region (CDR) domains of the 2E8 monoclonal antibodies. In another embodiment, the antibody or antibody fragment may comprise CDRs from these antibodies. In an embodiment, the antibody or antibody fragment comprises at least one or both of the CDR3 domains. In an embodiment, the domains of the antibody or antibody fragment have at least 90%, 95%, 97%, 99%, or 100% homology or identity with the domains present in the anti-human IDO2 antibodies or modifications as discussed above. Suitable routes of administering the antibody compositions described herein (e.g., human monoclonal antibodies, multi-specific and bispecific molecules and immune- conjugates, fragments or modifications) are in vivo and in vitro are well known in the art and can be selected by those of ordinary skill. In one embodiment, the antibody compositions can be administered by injection (e.g., intravenous or subcutaneous). Suitable dosages of the molecules used will depend on the age and weight of the subject and the concentration and/or formulation of the antibody composition. In general, regulatory agencies require that a protein reagent to be used as a therapeutic is formulated so as to have acceptably low levels of pyrogens. Accordingly,
therapeutic formulations will generally be distinguished from other formulations in that they are substantially pyrogen free, or at least contain no more than acceptable levels of pyrogen as determined by the appropriate regulatory agency (e.g., FDA). Therapeutic compositions may be administered with a pharmaceutically acceptable diluent, carrier, or excipient, in unit dosage form. Administration may be parenteral (e.g., intravenous, subcutaneous), oral, or topical, or intravenous, or by inhalation, as non-limiting examples. In addition, any gene therapy technique, using nucleic acids encoding the polypeptides of the invention, may be employed, such as naked DNA delivery, recombinant genes and vectors, cell-based delivery, including ex vivo manipulation of patients' cells, and the like. The concentration of the compound in the formulation varies depending upon a number of factors, including the dosage of the drug to be administered, and the route of administration. The antibodies as described herein will generally be administered to a patient as a pharmaceutical preparation. The term “patient” as used herein refers to human or animal subjects. These antibodies may be employed therapeutically, under the guidance of a physician for the treatment of the indicated disease or disorder. The pharmaceutical preparation comprising the antibody molecules of the invention may be conveniently formulated for administration with an acceptable medium (e.g., pharmaceutically acceptable carrier) such as water, buffered saline, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), dimethyl sulfoxide (DMSO), oils, detergents, suspending agents or suitable mixtures thereof. The concentration of the agents in the chosen medium may be varied and the medium may be chosen based on the desired route of administration of the pharmaceutical preparation. Except insofar as any conventional media or agent is incompatible with the agents to be administered, its use in the pharmaceutical preparation is contemplated. The dose and dosage regimen of an antibody according to the invention that is suitable for administration to a particular patient may be determined by a physician considering the patient's age, sex, weight, general medical condition, and the specific condition and severity thereof for which the antibody is being administered. The physician may also consider the route of administration of the antibody, the pharmaceutical carrier with which the antibody may be combined, and the antibody's biological activity. Selection of a suitable pharmaceutical preparation depends upon the method of administration chosen. For example, the antibodies of the invention may be administered by direct injection into any desired tissue or into the surrounding area. In this instance, a
pharmaceutical preparation comprises the antibody molecules dispersed in a medium that is compatible with the target tissue. Antibodies may also be administered parenterally, by intravenous injection into the blood stream, or by subcutaneous, intramuscular or intraperitoneal injection. Pharmaceutical preparations for parenteral injection are known in the art. If parenteral injection is selected as a method for administering the antibodies, steps must be taken to ensure that sufficient amounts of the molecules reach their target cells to exert a biological effect. The lipophilicity of the antibodies, or the pharmaceutical preparation in which they are delivered, may have to be increased so that the molecules can arrive at their target locations. Furthermore, the antibodies may have to be delivered in a cell-targeting carrier so that sufficient numbers of molecules will reach the target cells. Methods for increasing the lipophilicity of a molecule are known in the art. If a small form of the antibody is to be administered, including but not limited to a Fab fragment, a Dab, an scFv or a diabody, it may be conjugated to a second (carrier) molecule such as, but not limited to polyethylene glycol (PEG) or an albumin-binding antibody or peptide to prolong its retention in O blood. Pharmaceutical compositions containing an antibody of the present invention as the active ingredient in intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral. In preparing the antibody in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, to aid solubility or for preservative purposes, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. A pharmaceutical preparation of the invention may be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to a physically discrete unit of the pharmaceutical
preparation appropriate for the patient undergoing treatment. Each dosage should contain a quantity of active ingredient calculated to produce the desired effect in association with the selected pharmaceutical carrier. Procedures for determining the appropriate dosage unit are well known to those skilled in the art. Dosage units may be proportionately increased or decreased based on the weight of the patient. Appropriate concentrations for alleviation of a particular pathological condition may be determined by dosage concentration curve calculations, as known in the art. The appropriate dosage unit for the administration of anti-SARS-CoV-2 antibody molecules may be determined by evaluating the toxicity of the antibody molecules in animal models. Various concentrations of antibody pharmaceutical preparations may be administered to murine models of the disease or disorder and the minimal and maximal dosages may be determined based on the results and side effects as a result of the treatment. Appropriate dosage unit may also be determined by assessing the efficacy of the antibody molecule treatment in combination with other standard drugs. The dosage units of anti-SARS-CoV-2 antibody molecules may be determined individually or in combination with another treatment. The pharmaceutical preparation comprising the anti-SARS-CoV-2 antibody molecules may be administered at appropriate intervals, for example, at least twice a day or more until the pathological symptoms are reduced or alleviated, after which the dosage may be reduced to a maintenance level. The appropriate interval in a particular case would normally depend on the condition of the patient. The methods of the instant invention may further comprise monitoring the disease or disorder in the subject after administration of the composition(s) described herein to monitor the efficacy of the method. Antibody Co-administration with other Therapies for COVID-19 and/or SARS-CoV-2 In one embodiment, a patient with an active infection of SARS-CoV-2 or a patient with COVID-19, receives a treatment comprising at least one of the antibodies described herein in addition to an antiviral therapy, such as molnupiravir (Merck & Co., Inc. and Ridgeback Biotherapeutics) or remdesivir (Gilead Sciences, Inc.). In yet another embodiment, a patient with an active infection of SARS-CoV-2 or COVID-19 receives a treatment comprising at least one of the antibodies described herein in addition to at least one anti-inflammatory agent, such as tocilizumab (Genentech USA, Inc.) and lenzilumab (Humanigen, Inc.). In another embodiment, a patient with an active infection of SARS-CoV- 2 or COVID-19 receives a treatment comprising at least one of the antibodies described
herein in addition to at least one steroid, such as glucocorticosteroids, methylprednisolone, and dexamethasone. Other anti-inflammatory agents include, without limitation, non- steroidal anti-inflammatory drugs (NSAIDs; e.g., aspirin, ibuprofen, naproxen, methyl salicylate, diflunisal, indomethacin, sulindac, diclofenac, ketoprofen, ketorolac, carprofen, fenoprofen, mefenamic acid, piroxicam, meloxicam, methotrexate, celecoxib, valdecoxib, parecoxib, etoricoxib, and nimesulide ), corticosteroids (e.g., prednisone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, tramcinolone, and fluticasone), rapamycin, acetaminophen, glucocorticoids, steroids, beta- agonists, anticholinergic agents, methyl xanthines, gold injections (e.g., sodium aurothiomalate), sulphasalazine, and dapsone. In another embodiment, a patient with an active infection of SARS-CoV-2 or COVID-19 receives a treatment comprising at least one of the antibodies described herein in addition to at least one of the following: convalescent plasma or serum, intravenous immunoglobulins, eculizumab, heparin or another anticoagulant, angiotensin-converting enzyme (ACE) inhibitors, vitamin C, vitamin D, zinc, or n-acetylcysteine. Therapies for COVID-19 and/or SARS-CoV-2 In one embodiment, a patient diagnosed with a SARS-CoV-2 infection or COVID-19 using the methods described herein, receives a treatment comprising at least one of an antiviral therapy, such as molnupiravir (Merck & Co., Inc. and Ridgeback Biotherapeutics) or remdesivir (Gilead Sciences, Inc.); a neutralizing monoclonal antibody that targets SARS- CoV-2, such as sotrovimab (GlaxoSmithKline plc.), bamlanivimab (Eli Lilly and Co.), etesevimab (Eli Lilly and Co.), casirivimab (Regeneron Pharmaceuticals Inc.), and imdevimab (Regeneron Pharmaceuticals Inc.).; an anti-inflammatory agent, such as tocilizumab (Genentech USA, Inc.) and lenzilumab (Humanigen, Inc.); a steroid, such as glucocorticosteroids, methylprednisolone, and dexamethasone. Other treatments include anti- inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDs; e.g., aspirin, ibuprofen, naproxen, methyl salicylate, diflunisal, indomethacin, sulindac, diclofenac, ketoprofen, ketorolac, carprofen, fenoprofen, mefenamic acid, piroxicam, meloxicam, methotrexate, celecoxib, valdecoxib, parecoxib, etoricoxib, and nimesulide ), corticosteroids (e.g., prednisone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, tramcinolone, and fluticasone), rapamycin, acetaminophen, glucocorticoids, steroids, beta-agonists, anticholinergic agents, methyl xanthines, gold injections (e.g., sodium aurothiomalate), sulphasalazine, and dapsone.
In another embodiment, a patient with an active infection of SARS-CoV-2 or COVID-19 receives a treatment comprising at least one of the following: convalescent plasma or serum, intravenous immunoglobulins, eculizumab, heparin or another anticoagulant, angiotensin-converting enzyme (ACE) inhibitors, vitamin C, vitamin D, zinc, or n-acetylcysteine. Still other aspects and advantages of these compositions and methods are described further in the following detailed description of the preferred embodiments thereof. EXAMPLES The invention is now described with reference to the following examples. These examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these examples but rather should be construed to encompass any and all variations that become evident as a result of the teaching provided herein. The SARS-CoV-2 diagnostic paradigm has been challenged by the emergence of rapidly spreading variant strains that have important consequences for clinical and epidemiological decision making. Variant detection generally relies on Nucleic Acid Amplification Tests (NAATs). Immunoassays that detect viral antigens, e.g., antigen- detection rapid diagnostic tests (Ag-RDTs), may also be able to contribute by recognizing variant-specific epitopes, but monoclonal antibodies suitable for use in these assays have not been described. Described herein is a human mAb that binds N501 but not Y501 and can thus distinguish delta from other VBMs in an ELISA or other diagnostic assay. Furthermore, among the Y501-containing VOCs, the previously described human mAb CB6 binds alpha and gamma, but not beta. Diagnostic assays incorporating these two mAbs are useful for variant-specific SARS-CoV-2 POC testing. The foundation of the present work is a pair of human mAbs (2E8 and CB6) that differentially recognize SARS-CoV-2 VOCs and VOIs in an ELISA. Most of the VOCs and VOIs have acquired mutations in their spike glycoprotein, which mediates receptor binding and is one of the major targets of the adaptive immune response to SARS-CoV-2. Four hotspots within the receptor binding domain (RBD) undergo common mutations that may be targetable in Ag-RDTs (K417, L452, E484, N501) (Table 5).2E8 is a human mAb specific for N501; it does not bind spike RBDs that contain N501Y in an ELISA. CB6 is a previously described mAb that binds B.1.1.7 and P.1, but not B.1.351, in the ELISA, consistent with its previously described binding activities. Significantly, both mAbs bind to B.1.427, B.1.429,
and B.1.617. When used together, these two mAbs discriminate between clinically important SARS-CoV-2 VOCs and VBMs. Example 1: 2E8, a human mAb that neutralizes SARS-CoV-2 through spike RBD binding The 2E8 mAb was cloned from a male in his 50s who had a confirmed case of COVID-19 contracted in New York City in March 2020. A peripheral blood sample was obtained 42 days after his first symptom. The 2E8 mAb was cloned using the human hybridoma method described previously [36]. As antigens, we used VSV-G:S1 particles (pseudotyped with the SARS-CoV-2 spike protein S1 domain) and a trimeric, S1 protein (S1 trimer), both based on the reference sequence Wuhan-Hu-1 (L, NC_045512) [35]. We tested the hybridoma-expressed mAb for binding to commercial antigens (spike S1, spike D614G, and nucleocapsid) and the VSV-G:S1. In a direct ELISA, the 2E8 bound all four S1 antigens, with somewhat less binding to the VSV-G:S1 and the S1 trimer at the 0.1 µg/mL level (FIG. 1A). We then made a recombinant IgG12E8 molecule, which was used for all subsequent studies, as well as recombinant IgG1 mAbs, CB6 and CR3022 [32,41]. The 2E8 inhibited the binding of S1 to the 293T-hsACE2 cell line, reducing the amount of right-shifted cells from ~33% to 7.5%, compared to the 4G1 isotype control (FIG. 1B). The CB6 mAb also inhibited S1 binding (5%), whereas the CR3022 did not inhibit S1 binding despite adhering to S1 at the cell surface. To test viral neutralization, we used a reporter viral particle (RVP) assay, in which 293T-hsACE2 cells were incubated with SARS- CoV-2 (Wuhan-Hu-1 strain) pseudotyped virions that contain a luciferase transgene (FIG. 1C). Cells were infected in triplicate. The data were normalized to the negative control wells and calculated as the % infection. The 2E8 substantially reduced luciferase expression (80% reduction at 10 µg/mL) compared to the 6A non-binding control mAb, the non-neutralizing CR3022 mAb, and a polyclonal IgG (P24) from the B cell donor sampled for 2E8 mAb cloning. However, its activity was 100-fold less than that of the CB6 mAb (85% reduction at 0.1 µg/mL). We measured the binding kinetics of the 2E8 with the Wuhan-Hu-1 S1 using the OpenSPR™ Benchtop SPR System (Nicoya Lifesciences, Kitchener, ON, Canada). The Kinetic analysis is shown in FIG.1D: KD = 7.4 ± 0.58 nM, kon = 1.4 × 105 M−1 s−1 ± 2.0 × 103 M−1 s−1, koff = 9.6 × 10−4 ± 5.6× 10−5 s−1 (FIG.1D). This is approximately a three-fold lower affinity than that of the CD6 mAb, 2.49 ± 1.65 nM [32]. The full immobilization sequence of the SARS-CoV-2 S1 domain and 2E8 binding to the immobilized S1 domain are shown in FIG.6 and FIG.7A – FIG.7C, respectively. To gain more insight into the nature of S1 binding, we epitope binned the 2E8 in
comparison to the CB6 and CR3022 mAbs and a neutralizing, pan-specific anti-spike mouse mAb (Sino Biologicals, RRID: AB_2857934) on the Wuhan-Hu-1 S1 and RBD proteins. We used a binding assay that analyzes mAb competition at the linear portion of an antigen binding curve [43,44]. The 2E8 epitope on S1 and RBD clearly overlaps with CB6 but not CR3022 or the mouse mAb (FIG.2A, FIG.2B). This is consistent with the observations that CB6 binds S1 in a configuration that overlies the N501 residue and that CB6 and CR3022 bind non-overlapping epitopes [32,41]. Murine mAb binding was not inhibited by 2E8 or CB6, suggesting that it can be used in combination with these mAbs in a SARS-CoV-2 sandwich ELISA (FIG.2C, FIG.2D). Example 2: 2E8 binding to SARS-CoV-2 Variants of Concern Present and previously designated VOCs contain mutations in the RBD that can affect binding by mAbs. We used a direct ELISA to compare the binding of 2E8 and CB6 to recombinant S1 and RBD proteins, including S1 proteins corresponding to L, alpha, beta, gamma, and epsilon (B.1.429; L452R, E484Q). We also tested RBDs corresponding to delta, kappa (B.1.617.1; L452R, E484Q), and the single mutant K417N. The 2E8 bound all the spike proteins tested, except for alpha, beta, and gamma (FIG.3A). As these VBMs share the N501Y RBD mutation, and the alpha contains only the N501Y mutation, we also tested 2E8 binding to an N501Y RBD; no binding was observed (data not shown). In contrast, 2E8 binding to RBDs with a single K417N or E484K mutation was not impaired (FIG.3B). This suggests that the 2E8 interacts with N501 but not substantially with E484 or K417. Equivalent binding to delta, kappa, and epsilon S1 proteins further indicates that 2E8 does not recognize L452 or T478. This indicates that the 2E8 can distinguish between N501 and N501Y independent of changes affecting class I (K417) and class II (E484) neutralizing antibodies. CB6 is a well characterized, potent neutralizing mAb that shows reduced neutralization activity against many VBMs. CB6 shows no binding to beta and reduced binding to gamma but no reduction in binding to alpha, delta, kappa, or epsilon (FIG.3B). We explored the difference between binding to the beta and gamma RBDs, which differ only at K417 (beta, K417N; gamma, K417T). K417N by itself significantly reduces binding (FIG. 3B). This is consistent with the observations of others [45] and suggests that CB6 is useful to differentiate N501Y-containing variants alpha and gamma from beta in an ELISA. The murine mAb bound to every antigen tested, indicating its suitability as a capture mAb in variant-specific sandwich ELISAs (FIG.3C).
Example 3: Spike variant binding in a sandwich ELISA Sandwich ELISAs can be used to evaluate mAbs for use in LFAs, as both formats use a pair of non-overlapping mAbs for antigen capture and detection. We tested 2E8 and CB6 binding to variants in a sandwich ELISA format, including an anti-6X His tag antibody (Abcam, Cat: ab18184) as a positive control for antigen capture. The mAbs were used to capture the spike antigens, which were then detected with the biotinylated murine mAb (FIG. 4A). We tested binding to the same antigens tested in FIG.3A – FIG.3C. The 2E8 ELISA bound to L, delta, the K417N mutant, kappa, and epsilon but not to any of the Y501- containing variant proteins: alpha, beta, and gamma. CB6 bound every antigen except beta. As in the direct ELISA, reduced CB6 binding was seen with the gamma and K417N RBDs. The Anti-6X His tag antibody gave an equivalent signal with all antigens. These results are summarized in Table 5. Taken together, these results confirm the utility of the 2E8 mAb to differentiate variants by distinguishing N501 from Y501 in the spike RBD. They further show that CB6 can be used in this format to differentiate Y501-containing VBMs alpha and gamma from beta. Table 5. Antibody binding in sandwich ELISAs to SARS-CoV-2 variants
The emergence of SARS-CoV-2 variants has greatly complicated the efforts to control and treat the disease. The variants differ in their ability to evade antibody immunity provided by vaccination or passive immunization and, therefore, may dramatically impact health care facilities, congregate housing settings, public transportation hubs, and high-risk
occupational environments. Variant-specific POC testing is necessary to protect individuals in these settings, as well as to screen populations for shifts in SARS-CoV-2 epidemiology. This study advances the concept of using variant-specific Ag-RDTs as a component of the SARS-CoV-2 screening and diagnostic paradigm. Detection of the N501Y spike mutation with the 2E8 mAb is an efficient way distinguish delta from variants with the N501Y meta-signature [11], such as beta, gamma, mu, C.1.2, and novel N501Y-containing variants yet to emerge. The N501Y mutation has originated independently within multiple viral lineages and is positively selected because it increases infectivity through enhanced ACE2 binding [11,12]. Mutagenesis and modeling experiments suggest that the N501Y mutation will support the evolution of SARS-CoV-2 variants with increased infectivity and resistance to vaccines and therapeutics [13,45]. As the delta variant is currently the dominant strain globally, an Ag-RDT to detect infections with N501Y meta-signature variants will be a powerful tool for disease monitoring and control. The N501 residue lies on the “right shoulder” of the RBD and directly interacts with ACE2 during cell binding [11,12]. The N501Y mutation does not dramatically alter the overall RBD structure. This suggests that 2E8 binds N501 and/or may be sterically inhibited by Y501. The 2E8 binding site overlaps the CB6 site, yet its binding is not affected by changes at K417, and CB6 binding is largely insensitive to the N501Y change [12]. Furthermore, 2E8 has ~100-fold less neutralizing activity than that of CB6, even though its affinity is only 3-fold lower than that of the CB6 (7.38 ± 0.58 nM vs.2.49 ± 1.65 nM) [32]. These data highlight the structural independence of these two epitopes in variant RBDs. The CB6 interaction with the spike has been defined using X-ray crystallography [32]. CB6 is a type I neutralizing mAb that contacts the K417 and N501 residues. CB6 neutralization is unaffected by the N501Y RBD mutation, consistent with the relative unimportance of this residue to CB6 binding. In contrast, the gamma and beta variant changes essentially eliminate CB6 binding and neutralization [46,47,48]. Published data show that CB6 binding affinities for the beta and gamma variants are 42.6-fold and 18.7-fold lower, respectively, in comparison to the wild-type spike. This is attributable to the K417N mutation, which alone reduces affinity 21.9-fold compared to a 13.8-fold reduction from the K417T change. Our results are consistent with these data, which explain how CB6 distinguishes beta from alpha and gamma in our ELISAs. The 2E8 and CB6 mAbs provide qualitatively different information, because the 2E8 is a poorly neutralizing non-clinical antibody, whereas the CB6 is part of the etesevimab/bamlanivimab therapeutics. A lack of 2E8 binding to a clinical sample suggests
additional mutations associated with an increased risk of breakthrough infections and treatment failures. In contrast, a lack of CB6 binding strongly suggests that either the beta or gamma variant is present; furthermore, it predicts resistance to etesevimab. In the current delta-dominant milieu, either finding would ideally trigger a follow-up characterization using an NAAT test. This study supports a paradigm for the detection of SARS-CoV-2 variants using an Ag-RDT with variant-specific mAbs. The mAb capture/detection pairs used can be readily adaptable for use in LFAs. Ideally, the 2E8 mAb would be used in a multiplexed assay in parallel with a mAb or ACE2 reagents capable of binding all variants [49,50,51]. Such tests can be an important adjunct to NAATs, as they are ideal for POC testing to protect vulnerable populations and broaden epidemiological surveillance. Both 2E8 and CB6 have immediate applicability for testing while delta is the most prevalent variant. However, additional mAbs will be needed as the variant landscape evolves. This objective should be achievable, as the repertoire of potential variant-specific mutations is well-defined, a large number of anti-spike mAbs have been cloned, and extensive structural data describing mAb–spike interactions have been generated. Example 4: Materials and Methods SARS-CoV-2 spike antigens and antibodies A Wuhan-Hu-1 SARS-CoV-2 spike protein cDNA was cloned into the XhoI and NheI sites of a modified recombinant VSV vector containing an additional transcription start/stop signal between the G and L genes. The recombinant virus was recovered on 293T cells as described previously [33] and filtered through 0.22 µm PVDF filters (MilliporeSigma, Burlington, MA, USA)). The filtered virus was then used to inoculate human BEAS-2B lung cells (gift from R. Plemper, University of Georgia) seeded in Cellstack culture chambers (Corning, Corning, NY, USA). The infected cells were cultured in serum-free Optipro medium (Invitrogen, Waltham, MA, USA). Cell culture supernatant was harvested three days post-inoculation, clarified by centrifugation at 3000 g, and filtered through 0.45 µm PES membrane filters (Nalgene, Rochester, NY, USA). The filtered supernatant was layered on 20% sucrose in DPBS, and particles were sedimented by ultracentrifugation in a SW32 rotor (Beckman, Brea, CA, USA) for 1.5 h at 25,000 rpm. Viral particles were resuspended in phosphate-buffered saline and inactivated with 0.05% beta-propiolactone (BPL). After overnight incubation at 4 °C, the particles were incubated at 37 °C for 45 min to hydrolyze BPL and filtered through 0.22 µm PES filters (MilliporeSigma). To separate the
glycoproteins from the ribonucleoprotein complex, 2% beta-octyl-glucopyranoside (OGP) was added to the viral particles. After 15 min incubation at room temperature, the mixture was centrifuged for 1.5 h in a SW55 rotor (Beckman) at 45,000 rpm. After centrifugation, the supernatant was collected and filtered through 0.22 µm PES filters. For protein analysis, 3 µg particles and 1 µg OGP-solubilized glycoproteins were resolved on a denaturing SDS- polyacrylamide gel. (FIG.5). The gel was fixed and stained with SYPRORuby (Thermo Fisher Scientific, Waltham, MA, USA) according to the instructions provided by the manufacturer. Images of the stained gel were acquired on a Fluochem M instrument (Biotechne, Minneapolis, MN, USA). We also expressed a SARS-CoV-2 S1 domain fragment as a trimeric protein in Expi- 293F cells, in part following [34] (FIG.5). We used the original L strain sequence (GenBank: NC_045512) [35] and produced a fusion protein that included residues G283-F718 (eliminating the S1 amino terminal domain and extending to the S1–S2 boundary) and a mutated furin cleavage site. The fusion protein included a mu-phosphatase signal peptide (N- terminal) and a C-terminal fibritin T4 trimerization domain, followed by a Myc site and a 6XHis tag. A gene encoding this fusion protein was produced by Twist Bioscience (South San Francisco, CA, USA) and cloned into the pTwist CMV BetaGlobin expression vector. The construct was transiently transfected into Expi-293F cells (Thermo Fisher) following the manufacturer’s instructions. Due to limited secretion of the protein, on Day 5, we pelleted the cells by centrifugation at 3000 rpm at 4 °C for 20 min. The pellet was resuspended in Takara xTractor™ buffer (Takara Bio, Mountain View, CA, USA) with GenDEPOT Protease Inhibitor Cocktail II, EDTA Free (10X) (Thermo Fisher), incubated on ice with intermittent mixing for 15 min, and then centrifuged at 3500 rpm for 15 min at 4 °C. The supernatant was filtered through a 0.45 μm filter, and the protein was isolated with a Capturem™ His-Tagged Purification Column (Takara). The purity and integrity of S1 trimer were assessed by SDS:PAGE (data not shown) and Western blot (FIG.5) and detected with the Anti-6X His tag® antibody [HIS.H8] (Cat: ab18184; Abcam, Cambridge, MA, USA) and Peroxidase AffiniPure Goat Anti-Mouse IgG, Fcγ fragment specific (RRID: AB_2313585, Jackson ImmunoResearch, West Grove, PA, USA). A recombinant S1 fragment trimer (S1-trimer): We also expressed a SARS-CoV-2 S1 domain fragment as a trimeric protein in Expi-293F cells, in part following [32] (FIG.5). We used the original L strain sequence (GenBank: NC_045512) [21] and produced a fusion protein that includes residues G283-F718 (eliminating the S1 amino terminal domain and extending to the S1-S2 boundary) and a mutated furin cleavage site. The fusion protein
included a mu-phosphatase signal peptide (N-terminal) and a C-terminal fibritin T4 trimerization domain, followed by a Myc site and a 6XHis tag. A gene encoding this fusion protein was synthesized by Twist Bioscience (South San Francisco, CA) and cloned into the pTwist CMV Beta Globin expression vector. The construct was transiently transfected into Expi-293F cells (Thermo Fisher Scientific, Waltham, MA) following the manufacturer’s instructions. Due to limited secretion of the protein, on Day 5 we pelleted the cells by centrifugation at 3000 rpm at 4 °C for 20 minutes. The pellet was resuspended in Takara xTractor™ buffer (Takara Bio, USA, Mountain View, CA) with GenDEPOT Protease Inhibitor Cocktail II, EDTA Free (10X) (Thermo Fisher), incubated on ice with intermittent mixing for 15 minutes, then centrifuged at 3500rpm for 15 minutes at 4 °C. The supernatant was filtered through a 0.45 μm filter and protein was isolated with a Capturem™ His-Tagged Purification Column (Takara). The purity and integrity of S1-F-trimer was assessed by SDS:PAGE (data not shown) and Western blot (FIG.5), and was detected with the Anti-6X His tag® antibody [HIS.H8] (Cat: ab18184; Abcam, Cambridge, MA) and Peroxidase AffiniPure Goat Anti-Mouse IgG, Fcγ fragment specific (RRID: AB_2313585, Jackson ImmunoResearch, West Grove, PA). Commercial antigens The following S1 antigens were obtained from Sino Biological, Chesterbrook, PA: Wuhan-Hu-1 S1 (L): SARS-CoV-2 (2019-nCoV) Spike S1-His Recombinant Protein (Cat: 40591-V08H); Wuhan-Hu-1 S1 with D614G: SARS-CoV-2 (2019-nCoV) Spike S1 (D614G)-His Recombinant Protein (Cat: 40591-V08H3); Wuhan-Hu-1 RBD (L): SARS- CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein (Cat: 40592-V08H); alpha S1 (B.1.1.7, UK): SARS-CoV-2 (2019-nCoV) Spike S1(HV69-70 deletion, Y144 deletion, N501Y, A570D, D614G, P681H)-His Recombinant Protein (Cat: 40591-V08H12); beta S1 (B.1.351, South Africa), only RBD and D614G changes: SARS-CoV-2 (2019-nCoV) Spike S1(K417N, E484K, N501Y, D614G)-His Recombinant Protein (Cat: 40591-V08H10); beta S1 (B.1.351, South Africa): SARS-CoV-2 (2019-nCoV) Spike S1 (L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G)-His Recombinant Protein (Cat# 40591-V08H15); gamma RBD (P.1, Brazil/Japan): SARS-CoV-2 (2019-nCoV) Spike RBD (K417T, E484K, N501Y) Protein (His Tag) (Cat: 40592-V08H86); gamma S1 (P.1, Brazil/Japan): SARS-CoV-2 (2019-nCoV) Spike S1 (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y) Protein (His Tag) (Cat# 40591-V08H14); epsilon S1 (B.1.429, California): SARS-CoV-2 (2019-nCoV) Spike S1 (W152C, L452R, D614G) Protein (His Tag) (Cat: 40591-V08H17); kappa RBD (B.1.617.1, India): SARS-CoV-2
(2019-nCoV) Spike RBD (L452R, E484Q) Protein (His Tag) (Cat# 40592-V08H88); delta RBD (B.1.617.2, India): SARS-CoV-2 Spike RBD (L452R, T478K) Protein (His Tag) (Cat# 40592-V08H90); N501Y (alpha) RBD: SARS-CoV-2 (2019-nCoV) Spike RBD (N501Y)- His Recombinant Protein (Cat# 40592-V08H82); E484K RBD: SARS-CoV-2 (2019-nCoV) Spike RBD(E484K)-His Recombinant Protein (Cat# 40592-V08H84); K417N RBD: SARS- CoV-2 (2019-nCoV) Spike RBD (K417N)-His Recombinant Protein (Cat# 40592-V08H59); Wuhan-Hu-1 S1 (L) biotinylated: SARS-CoV-2 (2019-nCoV) Spike S1-His Recombinant Protein, Biotinylated (Cat: 40591-V08H-B). Example 5: 2E8 monoclonal antibody isolation We collected sera and peripheral blood mononuclear cells (PBMCs) from 25 patients at least 14 days following complete recovery from a SARS-CoV-2 infection. All subjects provided signed informed consent under a protocol approved by the Main Line Hospitals Institutional Review Board. We assayed the sera for immunoreactivity with the SARS-CoV-2 S1 pseudotyped VSV (VSV G:S1) particles by ELISA. A male volunteer in his 50s was found to have anti-spike titers >1:8000. He was a Caucasian, without comorbid health conditions, diagnosed by RT-PCR testing in New York City in March 2020. He required hospitalization due to respiratory decompensation but was not intubated. Blood was sampled 25 days after his last COVID-19-related symptom. We fused CD27+ peripheral blood mononuclear cells and the LCX OCMS fusion partner cell line [36]. Hybridomas were screened for binding to the VSV G:S1 particles by ELISA. A positive well was subjected to three rounds of single-cell cloning to isolate a monoclonal cell expressing the anti-SARS CoV-2 mAb, 2E8. For scale up, the hybridoma was adapted to 5% Ultra Low IgG FBS (Thermo Fisher), and the mAb was isolated from the supernatant using a Pierce™ Protein G column (Cat: 89927; Thermo Fisher). The 6A control mAb was also produced from its hybridoma [37]. The 2E8 Ig variable domains were amplified by RT-PCR, using the Qiagen RNA extraction kit (Cat: 74124; Qiagen, Germantown, MD, USA), and reverse transcribed with the Omniscript RT Kit (Cat: 205111; Qiagen). Variable domain cDNA sequences were amplified with consensus primer sets specific for human immunoglobulin heavy and light chain genes [38]. Amplified sequences were isolated by agarose gel electrophoresis, purified with the QiaQuick Gel Extraction kit (Cat: 28706; Qiagen), sequenced by Psomagen, Inc. (Rockville, MD, USA), and analyzed with IMGT/V-QUEST [39]. We also isolated polyclonal IgG from plasma of the individual who provided the 2E8 mAb, using a Pierce™ Protein G column (Thermo Fisher).
Production of recombinant antibodies For recombinant 2E8 production, full-length human IgG1 and Igλ cDNAs encoding the 2E8 mAb heavy and light chain variable regions were produced and subcloned into pTwist CMV BetaGlobin expression plasmids (Twist Bioscience) [40]. The plasmids were transiently transfected into Expi-293F cells following the manufacturer’s instructions. On day 4, cell culture supernatants were harvested and purified with the Pierce™ Protein G column (Thermo Fisher). Purity and size were confirmed by SDS:PAGE (data not shown). The 2E8 mAb concentration was measured with a NanoDrop1000 (Thermo Fisher). Recombinant human mAbs CB6 [32], CR3022 [41], and 4G1 [42] were produced by the same method. Surface Plasmon Resonance (SPR) Spectroscopy The binding kinetics of the 2E8 IgG with the SARS-CoV-2 S1 protein was determined using the 2-channel OpenSPR (Nicoya Lifesciences, Kitchener, ON). The assays were performed at 21 °C with buffer PBS 0.05% Tween-20 (PBST). The S1 protein (Wuhan-Hu-1 S1 (L): SARS-CoV-2 (2019-nCoV) Spike S1-His Recombinant Protein (Cat: 40591-V08H)) was immobilized on a nitrilotriacetic acid (NTA) sensor chip following EDTA conditioning. His-streptavidin (Abcam, Cat: ab78833) was immobilized in the reference channel as a control ligand. Purified recombinant 2E8 mAb was diluted in PBST supplemented with 0.1% BSA and injected for 5 min at a flow rate of 20 μL/min in a concentration series from 1.23 nM to 100 nM, with 10 min dissociation time. Sensors were regenerated with two injections of 500mM imidazole per regeneration step, with 40 s contact time and 270 s dissociation time. Sensorgrams were fitted with Trace Drawer analysis software (Ridgeview Instruments, Uppsala, Sweden). ELISAs Recombinant antibody binding to SARS-CoV-2 spike antigens: Recombinant antibody binding to SARS-CoV-2 spike antigens: NUNC high-binding ELISA plates (Thermo Fisher) were coated in PBS with 500 ng/well antigen at 4 °C overnight. Plates were washed three times with PBS containing 0.05% Tween-20 (PBST) and blocked with blocking buffer (BB) (PBST containing 5% non-fat dry milk) at 37 °C for one hour. Ten-fold serial dilutions of the mAbs were diluted in BB, added in triplicate, and incubated for 1 h at 37 °C. Following 3 washes with PBST, samples were incubated with horseradish peroxidase (HRP)-conjugated mouse anti-human IgG Fc fragment specific secondary antibody (RRID AB_2687484; Southern Biotech, Birmingham, AL, USA), diluted 1:1500 in BB, for one hour at 37 °C. After three washes, the plate was incubated with OPD substrate (P8287; Sigma Aldrich, St. Louis, MO, USA) for 10 min at RT. The reaction was stopped with 1N HCL, and the optical density
(OD) at 490 nm was read with a Biotek Synergy II microplate reader (BioTek Instruments, Winooski, VT, USA). The mouse mAb positive control was SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody (RRID:AB_2857934; Sino Biological) and was detected with Goat Anti-Mouse Ig, Human ads-HRP (Cat: 1010-05; Southern Biotech). Sandwich ELISAs for specific variant binding: Sandwich ELISAs for specific variant binding: NUNC high-binding ELISA plates were coated with 100 ng/well 2E8 or CB6 or 500 ng/well anti-6X His tag® antibody [HIS.H8] (RRID:AB_444306; Abcam), in PBS overnight at 4 °C. Plates were washed and blocked as above. S1 or RBD proteins were added to the plates (500 ng/well) and incubated for 1 h at 37 °C, followed by 3 washes. Biotinylated mouse anti-S1 (RRID:AB_2857934; Sino Biological), biotinylated with EZ-Link Sulfo-NHS- Biotin, (Thermo Fisher), was added (500 ng/well) and incubated for 1 h at 37 °C followed by 3 washes. Pierce Streptavidin-HRP substrate (Thermo Fisher) was added at 1:2000 dilution and incubated for 1 h at 37 °C and washed as above, and then the plates were washed and detected with OPD substrate as above. Example 7: Flow cytometry-based receptor-binding inhibition assay Antibody interference of S1 binding to human ACE2 receptor on the cell surface of 293T cells was measured by flow cytometry. Briefly, 0.1 μg/mL biotinylated SARS-CoV-2 spike S1 (Cat: 40591-V08H-B; Sino Biological) was incubated with 1 μg/mL recombinant mAb or a human ACE2-Fc fusion protein (Cat fc-hace2: Invivogen, San Diego, CA, USA) at 37 ºC for one hour. The S1:mAb mixtures were added to 5 × 105293T-hsACE2 cells (Cat: C-HA101; Integral Molecular) and incubated for 30 min at room temperature. Following incubation, cells were washed twice with PBS containing 2% fetal bovine serum (PBSF) and incubated with Alexa Flour 488 Streptavidin (RRID: AB_2337249; Jackson ImmunoResearch) (1:200 dilution) to detect S1 binding and Goat Anti-Human IgG (H + L) Antibody, Alexa Fluor 647 Conjugated (RRID:AB_2535862; Thermo Fisher) to detect human IgG binding. After 30 min incubation, cells were washed twice with PBSF and analyzed using a BD FACS Canto II (Becton Dickson, Franklin Lakes, NJ, USA). Data were analyzed using FlowJo 10.6.1. software (Tree Star, Ashland, OR, USA). Example 8: Pseudotyped SARS-CoV-2 antibody neutralization assay The antibody neutralization assay was obtained from Integral Molecular and performed following their protocol, using the 293T-hsACE2 cell line (Cat: C-HA101; Integral Molecular, Philadelphia, PA, USA) and the pseudotyped SARS-CoV-2 (Wuhan-Hu-
1 strain) reporter viral particles (RVPs) with luciferase (Cat: RVP-701L, Lot CL-114B, Integral Molecular). Briefly, in a 96-well plate, 5-fold serially diluted mAbs were combined with 10 μL RVPs and incubated for 1 h at 37 °C. Following incubation, 2 × 104293T- hsACE2 cells were added to each well, mixed gently by pipetting, and then incubated at 37° C with 5% CO2. After 72 h, SARS-CoV-2 RVP infection was quantified using the Renilla- Glo® Luciferase Assay System (Cat: E2710, Promega, Madison, WI, USA). Briefly, we centrifuged the plate for 5 min at 2000 rpm, aspirated the supernatants, and added 30 μL PBS to each well, followed by 30 µL Renilla-Glo® Assay Substrate (1:100 dilution). After 10 min, relative luminescence values were measured using the Synergy 2 plate reader (BioTek Instruments). The values from the negative control wells were normalized and used to calculate the percent infection for each concentration. All samples were run in triplicate. Example 9: Epitope binning We performed competitive binding assays to test whether biotinylated 2E8 could bind SARS-CoV-2 spike antigens (S1 and RBD) in the presence of the human mAbs CB6, CR3022, and the murine SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody (RRID:AB_2857934; Sino Biological) [43,44]. Black NUNC MaxiSorP 96-well plates (Thermo Fisher) were incubated overnight with 500 ng/well S1 or RBD, then washed three times with PBST, and blocked with BB for 1 h at 37 °C. The 2E8 was biotinylated with the EZ-Link Sulfo-NHS-Biotin kit (Thermo Fisher), and the S1 and sRBD antigen binding curves were found to be linear between 2.5 pg/mL and 2.5 μg/mL. In the experiments shown, 500 ng/well of the competing mAb was added to half of the antigen wells and PBS to the other half and then incubated for 1 h at 37 °C, followed by 3 PBST washes. The 2E8 serial dilution was added to the entire plate. After three more washes, Pierce Streptavidin-HRP substrate (Thermo Fisher) was added at 1:2000 dilution and incubated for 1 h at 37 °C. Following 3 PBST washes, SuperSignal ELISA Femto Substrate (Thermo Fisher) was added (1:1 ratio), and relative luminescence values were measured using the Synergy 2 plate reader (BioTek). Duplicate binding curves were plotted, and the linear portions were used for analysis. REFERENCES 1. Plante J.A., Mitchell B.M., Plante K.S., Debbink K., Weaver S.C., Menachery V.D. The variant gambit: COVID-19’s next move. Cell Host Microbe.2021;29:508–515. doi: 10.1016/j.chom.2021.02.020.
2. Tao K., Tzou P.L., Nouhin J., Gupta R.K., de Oliveira T., Kosakovsky Pond S.L., Fera D., Shafer R.W. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet.2021;22:757–773. doi: 10.1038/s41576-021-00408-x. 3. CDC SARS-CoV-2 Variant Classifications and Definitions. [(accessed on 22 October 2021)]; Available online: www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html 4. Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Consortium C.-G.U., et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol.2021;19:409–424. doi: 10.1038/s41579- 021-00573-0. 5. Garcia-Beltran W.F., Lam E.C., Denis K.S., Nitido A.D., Garcia Z.H., Hauser B.M., Feldman J., Pavlovic M.N., Gregory D.J., Poznansky M.C., et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell.2021;184:2372– 2383.e9. doi: 10.1016/j.cell.2021.03.013. 6. Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F., Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T., et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance.2021;26:2100509. doi: 10.2807/1560-7917.ES.2021.26.24.2100509. 7. Davies N.G., Abbott S., Barnard R.C., Jarvis C.I., Kucharski A.J., Munday J.D., Pearson C.A.B., Russell T.W., Tully D.C., Washburne A.D., et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science.2021;372 doi: 10.1126/science.abg3055. 8. Greninger A.L. Test it earlier, result it faster, makes us stronger: How rapid viral diagnostics enable therapeutic success. Curr. Opin. Virol.2021;49:111–116. doi: 10.1016/j.coviro.2021.05.007. 9. Mercer T.R., Salit M. Testing at scale during the COVID-19 pandemic. Nat. Rev. Genet.2021;22:415–426. doi: 10.1038/s41576-021-00360-w. 10. Eli Lilly and Company Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab; Revised 16 September 2021. [(accessed on 11 November 2021)]; Available online: www.fda.gov/media/145802/download 11. Martin D.P., Weaver S., Tegally H., San J.E., Shank S.D., Wilkinson E., Lucaci A.G., Giandhari J., Naidoo S., Pillay Y., et al. The emergence and ongoing convergent evolution of
the SARS-CoV-2 N501Y lineages. Cell.2021;184:5189–5200.e7. doi: 10.1016/j.cell.2021.09.003. 12. Supasa P., Zhou D., Dejnirattisai W., Liu C., Mentzer A.J., Ginn H.M., Zhao Y., Duyvesteyn H.M.E., Nutalai R., Tuekprakhon A., et al. Reduced Neutralization of SARS- CoV-2 B.1.1.7 Variant by Convalescent and Vaccine Sera. Cell.2021;184:2201–2211.e7. doi: 10.1016/j.cell.2021.02.033. 13. Zhu X., Mannar D., Srivastava S.S., Berezuk A.M., Demers J.P., Saville J.W., Leopold K., Li W., Dimitrov D.S., Tuttle K.S., et al. Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biol.2021;19:e3001237. doi: 10.1371/journal.pbio.3001237. 14. Zahradnik J., Marciano S., Shemesh M., Zoler E., Harari D., Chiaravalli J., Meyer B., Rudich Y., Li C., Marton I., et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat. Microbiol.2021;6:1188–1198. doi: 10.1038/s41564-021-00954-4. 15. Wang R., Chen J., Hozumi Y., Yin C., Wei G.W. Emerging vaccine-breakthrough SARS- CoV-2 variants. arXiv.20212109.04509v1 16. Scheepers C., Everatt J., Amoako D.G., Tegally H., Wibmer C.K., Mnguni A., Ismail A., Mahlangu B., Lambson B.E., Richardson S.I. Emergence and phenotypic characterization of C.1.2, a globally detected lineage that rapidly accumulated mutations of concern. medRxiv.2021 doi: 10.1101/2021.08.20.21262342. 17. Laiton-Donato K., Franco-Munoz C., Alvarez-Diaz D.A., Ruiz-Moreno H.A., Usme-Ciro J.A., Prada D.A., Reales-Gonzalez J., Corchuelo S., Herrera-Sepulveda M.T., Naizaque J., et al. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infect. Genet. Evol.2021;95:105038. doi: 10.1016/j.meegid.2021.105038. 18. Lucas C., Vogels C.B.F., Yildirim I., Rothman J.E., Lu P., Monteiro V., Gelhausen J.R., Campbell M., Silva J., Tabachikova A., et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature.2021;594:259–264. doi: 10.1038/s41586-021- 04085-y. 19. Uriu K., Kimura I., Shirakawa K., Takaori-Kondo A., Nakada T.-A., Kaneda A. Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera. bioRxiv.2021 doi: 10.1101/2021.09.06.459005.
20. Ooi K.H., Liu M.M., Tay J.W.D., Teo S.Y., Kaewsapsak P., Jin S., Lee C.K., Hou J., Maurer-Stroh S., Lin W., et al. An engineered CRISPR-Cas12a variant and DNA-RNA hybrid guides enable robust and rapid COVID-19 testing. Nat. Commun.2021;12:1739. doi: 10.1038/s41467-021-21996-6. 21. Bal A., Destras G., Gaymard A., Stefic K., Marlet J., Eymieux S., Regue H., Semanas Q., d’Aubarede C., Billaud G., et al. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to December 2020. Eurosurveillance.2021;26:2100008. doi: 10.2807/1560- 7917.ES.2021.26.3.2100008. 22. Vogels C.B.F., Breban M.I., Ott I.M., Alpert T., Petrone M.E., Watkins A.E., Kalinich C.C., Earnest R., Rothman J.E., Goes de Jesus J., et al. Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2. PLoS Biol.2021;19:e3001236. doi: 10.1371/journal.pbio.3001236. 23. Dinnes J., Deeks J.J., Berhane S., Taylor M., Adriano A., Davenport C., Dittrich S., Emperador D., Takwoingi Y., Cunningham J., et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst. Rev.2021;3:CD013705. doi: 10.1002/14651858.CD013705.pub2. 24. Harmon A., Chang C., Salcedo N., Sena B., Herrera B.B., Bosch I., Holberger L.E. Validation of an at-home direct antigen rapid test for COVID-19. JAMA Netw. Open.2021;4:e2126931. doi: 10.1001/jamanetworkopen.2021.26931. 25. Heidt B., Siqueira W.F., Eersels K., Dilien H., van Grinsven B., Fujiwara R.T., Cleij T.J. Point of care diagnostics in resource-limited settings: A review of the present and future of PoC in its most needed environment. Biosensors.2020;10:133. doi: 10.3390/bios10100133. 26. Peeling R.W., Olliaro P.L., Boeras D.I., Fongwen N. Scaling up COVID-19 rapid antigen tests: Promises and challenges. Lancet Infect. Dis.2021;21:e290–e295. doi: 10.1016/S1473- 3099(21)00048-7. 27. Larremore D.B., Wilder B., Lester E., Shehata S., Burke J.M., Hay J.A., Tambe M., Mina M.J., Parker R. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci. Adv.2021;7:eabd5393. doi: 10.1126/sciadv.abd5393. 28. Pekosz A., Parvu V., Li M., Andrews J.C., Manabe Y.C., Kodsi S., Gary D.S., Roger- Dalbert C., Leitch J., Cooper C.K. Antigen-based testing but not real-time polymerase chain
reaction correlates with severe acute respiratory syndrome coronavirus 2 viral culture. Clin. Infect. Dis.2021;73:e2861–e2866. doi: 10.1093/cid/ciaa1706. 29. Pickering S., Batra R., Merrick B., Snell L.B., Nebbia G., Douthwaite S., Reid F., Patel A., Kia Ik M.T., Patel B., et al. Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: A single-centre laboratory evaluation study. Lancet Microbe.2021;2:e461–e471. doi: 10.1016/S2666-5247(21)00143-9. 30. Lv Y., Ma Y., Si Y., Zhu X., Zhang L., Feng H., Tian D., Liao Y., Liu T., Lu H., et al. Rapid SARS-CoV-2 antigen detection potentiates early diagnosis of COVID-19 disease. Biosci. Trends.2021;15:93–99. doi: 10.5582/bst.2021.01090. 31. FDA In Vitro Diagnostics EUAs—Antigen Diagnostic Tests for SARS-CoV-2. [(accessed on 22 October 2021)]; Available online: www.fda.gov/medical- devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical- devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2 32. Shi R., Shan C., Duan X., Chen Z., Liu P., Song J., Song T., Bi X., Han C., Wu L., et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV- 2. Nature.2020;584:120–124. doi: 10.1038/s41586-020-2381-y. 33. Kurup D., Wirblich C., Feldmann H., Marzi A., Schnell M.J. Rhabdovirus-based vaccine platforms against henipaviruses. J. Virol.2015;89:144–154. doi: 10.1128/JVI.02308-14. 34. Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell.2020;181:281– 292.e6. doi: 10.1016/j.cell.2020.02.058. 35. Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., et al. A new coronavirus associated with human respiratory disease in China. Nature.2020;579:265–269. doi: 10.1038/s41586-020-2008-3. 36. Puligedda R.D., Sharma R., Al-Saleem F.H., Kouiavskaia D., Velu A.B., Kattala C.D., Prendergast G.C., Lynch D.R., Chumakov K., Dessain S.K. Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening. MAbs.2019;11:546–558. doi: 10.1080/19420862.2019.1574520. 37. Adekar S.P., Jones R.M., Elias M.D., Al-Saleem F.H., Root M.J., Simpson L.L., Dessain S.K. A human monoclonal antibody that binds serotype A botulinum
neurotoxin. Hybridoma.2008;27:11–17. doi: 10.1089/hyb.2007.0536. 38. Tiller T., Meffre E., Yurasov S., Tsuiji M., Nussenzweig M.C., Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods.2008;329:112–124. doi: 10.1016/j.jim.2007.09.017. 39. Giudicelli V., Brochet X., Lefranc M.P. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb. Protoc.2011;2011:695–715. doi: 10.1101/pdb.prot5633. 40. Vazquez-Lombardi R., Nevoltris D., Luthra A., Schofield P., Zimmermann C., Christ D. Transient expression of human antibodies in mammalian cells. Nat. Protoc.2018;13:99–117. doi: 10.1038/nprot.2017.126. 41. Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P., Wilson I.A. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science.2020;368:630–633. doi: 10.1126/science.abb7269. 42. Tursi S.A., Puligedda R.D., Szabo P., Nicastro L.K., Miller A.L., Qiu C., Gallucci S., Relkin N.R., Buttaro B.A., Dessain S.K., et al. Salmonella Typhimurium biofilm disruption by a human antibody that binds a pan-amyloid epitope on curli. Nat. Commun.2020;11:1007. doi: 10.1038/s41467-020-14685-3. 43. Al-Saleem F.H., Sharma R., Puligedda R.D., Elias M., Kattala C.D., Simon P.M., Simpson L.L., Dessain S.K. RBC adherence of immune complexes containing botulinum toxin improves neutralization and macrophage uptake. Toxins.2017;9:173. doi: 10.3390/toxins9050173. 44. Puligedda R.D., Kouiavskaia D., Al-Saleem F.H., Kattala C.D., Nabi U., Yaqoob H., Bhagavathula V.S., Sharma R., Chumakov K., Dessain S.K. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes. Vaccine.2017;35:5455– 5462. doi: 10.1016/j.vaccine.2017.03.038. 45. Wang R., Zhang Q., Ge J., Ren W., Zhang R., Lan J., Ju B., Su B., Yu F., Chen P., et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity.2021;54:1611– 1621.e1615. doi: 10.1016/j.immuni.2021.06.003. 46. Wang P., Casner R.G., Nair M.S., Wang M., Yu J., Cerutti G., Liu L., Kwong P.D.,
Huang Y., Shapiro L., et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe.2021;29:747–751.e744. doi: 10.1016/j.chom.2021.04.007. 47. Wang P., Nair M.S., Liu L., Iketani S., Luo Y., Guo Y., Wang M., Yu J., Zhang B., Kwong P.D., et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature.2021;593:130–135. doi: 10.1038/s41586-021-03398-2. 48. Dejnirattisai W., Zhou D., Supasa P., Liu C., Mentzer A.J., Ginn H.M., Zhao Y., Duyvesteyn H.M.E., Tuekprakhon A., Nutalai R., et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell.2021;184:2939–2954.e2939. doi: 10.1016/j.cell.2021.03.055. 49. Feuerstein G.Z., Mansfield M.A., Lelkes P.I., Alesci S., Marcinkiewicz C., Butlin N., Sternberg M. The use of near-infrared light-emitting fluorescent nanodiamond particles to detect Ebola virus glycoprotein: Technology development and proof of principle. Int. J. Nanomed.2020;15:7583–7599. doi: 10.2147/IJN.S261952. 50. Cantera J.L., Cate D.M., Golden A., Peck R.B., Lillis L.L., Domingo G.J., Murphy E., Barnhart B.C., Anderson C.A., Alonzo L.F., et al. Screening antibodies raised against the spike glycoprotein of SARS-CoV-2 to support the development of rapid antigen assays. ACS Omega.2021;6:20139–20148. doi: 10.1021/acsomega.1c01321. 51. Lee J.H., Choi M., Jung Y., Lee S.K., Lee C.S., Kim J., Kim J., Kim N.H., Kim B.T., Kim H.G. A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2) Biosens. Bioelectron.2021;171:112715. doi: 10.1016/j.bios.2020.112715. Each and every patent, patent application, and publication, including websites cited throughout the specification are incorporated herein by reference. Similarly, the SEQ ID NOs which are referenced herein and which appear in the appended Sequence Listing are incorporated by reference. US Provisional Patent Application No.63/253,178, filed October 7, 2021, is incorporated herein by reference. While the invention has been described with reference to particular embodiments, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims.
Claims
CLAIMS: 1. An antibody that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Wuhan S1 protein variant at N501, but does not bind a SARS-CoV-2 S1 protein variant that has a spike protein mutation N501Y, said antibody comprising: (a) a heavy chain variable region (VH) comprising (i) a complementarity- determining region 1 (CDR1) of SEQ ID NO: 15, (ii) a complementarity-determining region 2 (CDR2) of SEQ ID NO: 17, and (iii) a complementarity-determining region 3 (CDR3) of SEQ ID NO: 18; and/or (b) a light chain variable region (VL) comprising, (i) a CDR1 of SEQ ID NO: 22, (ii) a CDR2 having the amino acid sequence Asp-Asp-Ser (DDS), and (iii) a CDR3 of SEQ ID NO: 23.
2. The antibody of claim 1, comprising a VH having an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 14 and a VL having an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO: 21.
3. The antibody of claim 1 or 2, wherein the VH comprises the amino acid sequence of SEQ ID NO: 14 and the VL comprises the amino acid sequence of SEQ ID NO: 21.
4. The antibody of any one of claims 1 to 3, wherein the antibody is an IgG, an IgM, an IgE, an IgA, or an IgD isotype, or is derived therefrom.
5. The antibody of any one of claims 1 to 4, wherein the antibody comprises a monoclonal antibody, a grafted antibody, a chimeric antibody, a human antibody, or a non- human antibody.
6. The antibody of any one of claims 1 to 4, wherein the antigen-binding fragment is a Fab, F(ab’)2, Fab’, scFv, di-scFv, tri-functional antibody, chemically linked F(ab’)2, BiTE, or single domain antibody.
7. The antibody of any one of claims 1 to 6, which is synthetic or recombinant.
8. The antibody of any one of claims 1 to 7, which is conjugated to a synthetic molecule.
9. The antibody of claim 8, wherein the synthetic molecule is a label, a contrast agent, a magnetic nanoparticle, a cytotoxic agent, a cytostatic agent, an anti-angiogenic agent, or a radioisotope.
10. The antibody of claim 6, which is formatted as a non-human antibody, wherein the VH CDR1, CDR2 and CDR3 sequences of SEQ ID NOs: 15, 17, and 18 respectively and wherein the VL CDR1, CDR2, and CDR3 are SEQ ID No: 22, amino acid sequence DDS and SEQ ID No: 23, respectively.
11. A method of diagnosing a subject as being infected with a SARS-CoV-2 virus, the method comprising contacting a sample obtained from the subject with the antibody of any one of claims 1 to 10, to form an antibody/SARS-CoV-2 virus complex when the antigen is present in the sample, diagnosing the subject as being infected with a SARS-CoV-2 virus variant having the residue N501 and not N501Y, when the antibody/SARS-CoV-2 virus complex is detected.
12. A method of diagnosing a subject as being infected with a SARS-CoV-2 virus, the method comprising contacting a sample obtained from the subject with a panel of antibodies that bind selected S1 antigens in SARS-CoV-2 variants to form an antibody/SARS-CoV-2 virus complex when the antigen is present in the sample, wherein one antibody in the panel of antibodies is the antibody of any one of claims 1 to 10 that binds S1 antigens having only N501, not mutations at that site; detecting the pattern of binding between said antibodies by the presence or absence of an antibody/SARS-CoV-2 virus complex; and diagnosing the subject as being infected with a specific SARS-CoV-2 virus variant based upon the pattern of binding between the panel of antibodies and the viral S1 protein.
13. The method of claim 11 or 12, wherein the sample comprises a nasal swab, a tissue sample, saliva, or blood.
14. The method of claims 11 to 13, wherein detecting the presence or absence of
the antibody/SARS-CoV-2 virus complex or the antigen-binding fragment/SARS-CoV-2 virus complex comprises an enzyme linked immunosorbent assay (ELISA), an immunospot assay, a lateral flow assay, flow cytometry, immunohistochemistry, or a western blot.
15. The method of any one of claims 11 to 14, wherein said test is an Antigen Diagnostic Test immunoassay directed to detect at pattern of spike RBD polymorphisms at S1 amino acid residues K417, L452, E484, and N501, wherein the pattern detected by the selected antibodies or antigen binding fragments thereof distinguishes among SARS-CoV-2 variant infections.
16. The method of any one of claims 11 to 15, wherein said test further comprises a pan- SARS-CoV-2 specific antibody.
17. A diagnostic composition comprising the antibody of any one of claims 1 to 10 conjugated to or associated with a detectable label.
18. A cell transformed to express the antibody of any one of claims 1 to 10.
19. A diagnostic kit for the diagnosis of a SARS-CoV-2 variant comprising the antibody of any of claims 1 to 10 conjugated to or associated with a detectable label.
20. The diagnostic kit of claim 19, further comprising (b) a pan-SARS-CoV-2 specific antibody, conjugated to or associated with a detectable label.
21. The kit of claim 19 or 20, further comprising antibodies of (a) and/or (b), packaged in a container, a vial or bottle, further reagents essential for performing an ELISA, and a label attached to or packaged with the container, the label describing the contents of the container and providing indications and/or instructions regarding use of the contents of the container.
22. A pharmaceutical composition comprising the antibody of any one of claims 1 to 10, and a pharmaceutically acceptable carrier.
23. The pharmaceutical composition of claim 22, further comprising a second therapeutic agent.
24. A method of preventing or treating a SARS-CoV-2 viral infection or COVID19 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 22 or 23.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163253178P | 2021-10-07 | 2021-10-07 | |
US63/253,178 | 2021-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023060244A1 true WO2023060244A1 (en) | 2023-04-13 |
Family
ID=85803765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/077774 WO2023060244A1 (en) | 2021-10-07 | 2022-10-07 | Methods and compositions including novel antibodies for diagnosing covid-19 variants |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023060244A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018177220A1 (en) * | 2017-03-25 | 2018-10-04 | 信达生物制药(苏州)有限公司 | Anti-ox40 antibody and use thereof |
WO2019075433A1 (en) * | 2017-10-13 | 2019-04-18 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, methods of their generation and use |
WO2021194188A1 (en) * | 2020-03-22 | 2021-09-30 | (주)셀트리온 | Binding molecule having neutralizing activity against sars-coronavirus-2 |
-
2022
- 2022-10-07 WO PCT/US2022/077774 patent/WO2023060244A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018177220A1 (en) * | 2017-03-25 | 2018-10-04 | 信达生物制药(苏州)有限公司 | Anti-ox40 antibody and use thereof |
WO2019075433A1 (en) * | 2017-10-13 | 2019-04-18 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, methods of their generation and use |
WO2021194188A1 (en) * | 2020-03-22 | 2021-09-30 | (주)셀트리온 | Binding molecule having neutralizing activity against sars-coronavirus-2 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180208680A1 (en) | Antibodies for Botulinum Neurotoxins | |
US20220281958A1 (en) | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | |
CN106432484A (en) | Human immunodeficiency virus neutralizing antibodies and methods of use thereof | |
EP3970798A1 (en) | Sars-cov-2-nanobodies | |
US20230287089A1 (en) | Antigen Binding Molecules Targeting SARS-CoV-2 | |
JP2023534923A (en) | Antigen-binding molecule targeting SARS-CoV-2 | |
US20230122364A1 (en) | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | |
JP2023534922A (en) | Antigen-binding molecule targeting SARS-CoV-2 | |
EP4034238A1 (en) | Antibodies for the diagnosis and/or treatment of atherosclerosis | |
JP2018533938A (en) | Bactericidal monoclonal antibody targeting Klebsiella pneumoniae | |
CN105121466A (en) | Antibodies targeting m-csf | |
TWI793098B (en) | Anti-herv-k envelope antibody and uses thereof | |
WO2013109185A1 (en) | Novel antibodies | |
US20220073611A1 (en) | Anti-nmda receptor antibodies and methods of use | |
WO2020176871A1 (en) | Kawasaki disease antibodies identify hepacivirus peptides | |
WO2023060244A1 (en) | Methods and compositions including novel antibodies for diagnosing covid-19 variants | |
US20240150494A1 (en) | Glycoform specific nanobodies and methods of use | |
WO2022238481A1 (en) | Antibodies | |
US20230168249A1 (en) | Recombinant antibodies, kits comprising the same, and uses thereof | |
US20190240316A1 (en) | Human respiratory syncytial virus antibodies and methods of use therefor | |
WO2021058553A1 (en) | Methods for the diagnosis of atherosclerosis | |
EP4385999A1 (en) | Antibodies | |
US20230228763A1 (en) | Process for direct readout of immunoglobulins | |
US20230417748A1 (en) | Coronavirus Spike Protein-Specific Antibody and Use Thereof | |
US20230075982A1 (en) | Antibodies and assays for detection of burkholderia mallei |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22879523 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |